Site-specific risk factors for portal vein thrombosis and evaluation of anticoagulation efficacy in patients with cirrhosis by Rodriguez Castro, Kryssia Isabel
  
 
 
 
 
Sede Amministrativa: Università degli Studi di Padova 
 
 
Dipartimento Di Scienze Del Farmaco 
 
SCUOLA DI DOTTORATO DI RICERCA IN: Biologia e Medicina della 
Rigenerazione 
INDIRIZZO: Scienze Epatologiche e Gastroenterologiche  
CICLO: XXV 
 
 
SITE-SPECIFIC RISK FACTORS FOR PORTAL VEIN THROMBOSIS AND 
EVALUATION OF ANTICOAGULATION EFFICACY IN PATIENTS WITH 
CIRRHOSIS  
 
 
Direttore della Scuola: Ch.ma Prof.ssa Maria Teresa Conconi  
Coordinatore d’indirizzo: Ch.mo Prof. Giacomo Carlo Sturniolo  
Supervisori: Dott.ssa Patrizia Burra e Dott. Marco Senzolo 
 
 
 
     Dottorando:  Kryssia Isabel Rodríguez Castro 
 
 
1 
 
 
ABBREVIATIONS .................................................................... 5 
SUMMARY ............................................................................... 7 
RIASSUNTO .......................................................................... 10 
INTRODUCTION .................................................................... 13 
PROCOAGULANT FACTORS ...................................................... 13 
ANTICOAGULANT FACTORS ..................................................... 15 
OVERVIEW OF HEMOSTASIS ALTERATIONS IN CIRRHOSIS ............. 16 
THROMBIN GENERATION .......................................................... 19 
CLINICAL EVIDENCE OF PRO-THROMBOTIC COMPLICATIONS IN 
CIRRHOSIS ............................................................................. 23 
Venous thromboembolism ................................................ 23 
Portal vein thrombosis ...................................................... 24 
RISK FACTORS FOR THE DEVELOPMENT OF PORTAL VEIN 
THROMBOSIS IN CIRRHOSIS ...................................................... 25 
ENDOTHELIAL INJURY AND DEVELOPMENT OF PORTAL VEIN 
THROMBOSIS ......................................................................... 28 
CLINICAL CONSEQUENCES OF PORTAL VEIN THROMBOSIS IN 
CIRRHOSIS AND RATIONALE FOR TREATMENT ............................. 30 
AIMS ...................................................................................... 35 
I. ENDOTHELIAL DYSFUNCTION IN CIRRHOSIS: 
CHARACTERIZATION OF STRUCTURAL AND FUNCTIONAL 
ASPECTS OF THE PORTAL VEIN WHICH LEAD TO IN SITU 
THROMBOSIS ....................................................................... 37 
MATERIALS AND METHODS ...................................................... 37 
Venous samples ............................................................... 37 
Sample obtainment ........................................................... 38 
2 
 
Sample retrieval and conservation .................................... 38 
Immunohistochemical evaluation of FVIII .......................... 39 
Immonofluorescence evaluation of TM .............................. 39 
RESULTS ............................................................................... 41 
Characteristics of patients and controls ............................. 41 
Immunohistochemistry ...................................................... 43 
Immunofluorescence ......................................................... 44 
II.  PREDICTORS OF RESPONSE TO ANTICOAGULANT 
THERAPY IN CIRRHOSIS PATIENTS WITH PORTAL VEIN 
THROMBOSIS. ...................................................................... 45 
MATERIALS AND METHODS ...................................................... 45 
Patients ............................................................................. 45 
Definition of extent and age of thrombosis ........................ 45 
Thrombophilia screening ................................................... 46 
Anticoagulation protocol .................................................... 47 
Follow-up and imaging ...................................................... 48 
Analyzed variables ............................................................ 48 
Endpoints .......................................................................... 49 
Statistical analysis ............................................................. 50 
RESULTS ............................................................................... 51 
Patient and thrombus characteristics ................................ 51 
Recanalization under anticoagulation protocol .................. 52 
Factors associated with response to anticoagulation ........ 55 
III. ANTICOAGULANT RESPONSE TO LOW-MOLECULAR-
WEIGHT HEPARIN IN PLASMA FROM PATIENTS WITH 
ADVANCED CIRRHOSIS. ..................................................... 59 
MATERIALS AND METHODS ...................................................... 59 
Patients ............................................................................. 59 
Blood collection and plasma preparation ........................... 60 
3 
 
Thrombophilia screening and evaluation of coagulation 
factors ............................................................................... 60 
Addition of Enoxaparin to plasma samples ....................... 61 
Anti-Xa activity measurement ........................................... 61 
Thrombin Generation ........................................................ 62 
Statistical Analysis ............................................................ 63 
RESULTS ............................................................................... 64 
Patient characteristics and coagulation profile .................. 64 
 ......................................................................................... 66 
Determination of anti-Xa activity in plasma ....................... 66 
Thrombin generation ......................................................... 67 
DISCUSSION ......................................................................... 75 
CONCLUSIONS ..................................................................... 95 
BIBLIOGRAPHY .................................................................... 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
aPTT  Activated Partial Thromboplastin Time 
AT  Antithrombin 
CAT  Calibrated Automated Thrombogram  
CT  Computerized Tomography Scan 
DVT Deep Vein Thrombosis 
ELISA Enzyme-Linked Immunosorbent Assay 
ETP  Endogenous Thrombin Potential  
FII  Factor II 
FITC Fluorescein isothiocyanate 
FV  Factor V 
FVIII  Factor VIII 
FXa  Activated Factor X 
HIT Heparin-induced thrombocytopenia 
IgG Immunoglobulin G 
IL Interleukin 
INR  International Normalized Ratio 
LMWH Low Molecular Weight Heparin 
MRI Magnetic Resonance Imaging  
RNA Ribo-Nucleic Acid 
OCT Optimal Cutting Temperature Compound 
PBS Phosphate buffered saline 
PC  Protein C 
PE  Pulmonary Embolism 
PIVKA Proteins Induced by Vitamin K Absence 
PPP  Platelet-Poor Plasma 
PRP Platelet-Rich Plasma 
PVT  Portal Vein Thrombosis 
TG  Thrombin Generation 
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TM  Thrombomodulin 
TNF Tumor Necrosis Factor 
VKA Vitamin K Antagonists 
VTE  Venous Thromboembolism 
vWF von Willebrand Factor 
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Advanced liver disease is characterized by profound hemostatic 
alterations that can lead both to bleeding or to thrombotic complications.  
While pro-hemorrhagic alterations are present including thrombocytopenia 
and reduced plasmatic levels of coagulation factors, pro-thrombotic 
abnormalities such as decrease in anti-coagulant proteins antithrombin, 
Proteins C and S, increase in prothrombotic Factor VIII, and von 
Willebrand factor are also present. 
 
The most frequent site of thrombosis in cirrhotic patients is the portal vein, 
consequence of an interplay of factors including altered hemostasis and 
venous stasis.  The endothelium, the third component of the thrombosis 
triad, however, probably plays an important role in the genesis of in situ 
thrombosis within the portal vein.  In the present study, endothelium form 
portal and cava veins were analyzed in cirrhotic patients, and compared to 
that of non-cirrhotic subjects, in order to determine the possible role of 
local alterations in the development of thrombosis. The 
immunofluorescence study of the main endothelial anticoagulant protein, 
thrombomodulin, revealed decreased presence of this component in the 
endothelium of the portal vein with respect to the vena cava in cirrhosis 
patients.  On the other hand, the immunohistochemical analysis of pro-
coagulant Factor VIII revealed that this endothelial protein is present 
uninterruptedly lining the lumen of portal vein and vena cava of both 
cirrhosis patients and non-cirrhotic subjects, without showing any 
differences between them.  Diminished thrombomodulin may hamper the 
endothelium’s anticoagulant properties, which, in the presence of 
conserved Factor VIII, may lead to the development of thrombosis.  
The thrombosis of the portal vein represents an important milestone in the 
natural history of patients with cirrhosis, often increasing morbidity before 
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and mortality after liver transplantation.  Obtainment of recanalization 
through anticoagulation is therefore paramount, and in the present study, 
an analysis was performed regarding factors that may have an impact on 
efficacy of anticoagulation with low molecular weight heparin in cirrhotic 
patients with this complication.   Anticoagulation with low molecular weight 
heparin was demonstrated to be a valid strategy for achieving portal vein 
recanalization, with a response rate of 65.2%, including complete 
recanalization in 24 of the 46 treated patients, after a mean of 4.5 months 
(±3.1 months) of anticoagulation.  Whereas the hemostatic status of 
patients did not correlate with the response to anticoagulation, the interval 
between thrombus onset and start of therapy was the only predictive factor 
of therapeutic efficacy.  Specifically, thrombus age at diagnosis (1.9 ± 1.2 
months vs 6.3 ± 4.5 months in the recanalization group and in the non-
recanalization group, respectively, p<.001), and the interval between 
thrombus onset and start of anticoagulation (3.2 ± 1.7 months vs 7.78 ± 
4.5 months in the recanalization group and in the non-recanalization 
group, respectively, p<.002) were the principal determinants of therapeutic 
efficacy.  This underlines the importance of prompt diagnosis and start of 
therapy to increase the probability of successful anticoagulant therapy. 
 
Although in cirrhosis the low levels of antithrombin, which is necessary for 
the action of heparins, could theoretically hamper the anticoagulant effect, 
the clinical efficacy of anticoagulant therapy with low molecular weight 
heparin has been herein demonstrated.  
 
The anticoagulant effect of low molecular weight heparin was then tested 
in vitro using the thrombin generation assay, and concentrations within the 
therapeutic range achieved reduction of endogenous thrombin potential 
notwithstanding the marked reduction in antithrombin levels that were 
present in plasma from cirrhotic patients and the low plasma anti-Xa 
activity determined in vitro.  In particular, patients with Child Pugh C 
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cirrhosis were characterized by antithrombin levels which were as low as 
those of subjects with the prothrombotic condition of genetic antithrombin 
deficit (42±14% versus 52±4%, respectively,  p=.06). At low molecular 
weight heparin 0.35 UI/mL concentration in vitro, anti-Xa activity was 
significantly lower in Child Pugh B and Child Pugh C patients as compared 
to controls (p<0.001), as well as in patients with congenital AT defect as 
compared to controls (p<0.001). Despite low levels of antithrombin and 
anti-Xa activity, patients with cirrhosis showed a greater anticoagulant 
effect of low molecular weight heparin, with a mean endogenous thrombin 
potential reduction of 72.6±11% (p=0.02 versus controls). This increased 
susceptibility of cirrhosis patients with advanced stages of the disease 
may therefore actually warrant dose reduction of anticoagulation.  
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La cirrosi epatica avanzata è caratterizzata da alterazioni emostatiche 
importanti che possono portare a complicanze emorragiche o trombotiche.  
Nonostante siano presenti alterazioni pro-emorragiche come 
trombocitopenia e ridotti livelli dei fattori della coagulazione, sono presenti 
anche anormalità pro-trombotiche come la diminuzione di proteine anti-
coagulanti, quali antitrombina, Proteina C ed S, ed incremento del Fattore 
VIII e Fattore von Willebrand  . 
 
Il sito più frequente di trombosi in pazienti cirrotici è la vena porta, risultato 
di vari fattori quali le alterazioni emostatiche sistemiche così come la stasi 
venosa locale. Tuttavia, l’endotelio, il terzo componente del triade 
trombotica, probabilmente gioca un ruolo importante nella genesi della 
trombosi in situ della vena porta.  Nel presente studio, è stato analizzato 
l’endotelio della vena porta e comparato a quello della vena cava in 
pazienti cirrotici e non, per determinare il possibile ruolo delle alterazioni 
locali nello sviluppo della trombosi.  Come principale proteina endoteliale 
anticoagulante, è stata studiata la trombomodulina tramite 
immunofluorescenza, rivelandone una ridotta presenza nell’endotelio della 
vena porta rispetto a quello della vena cava nei pazienti cirrotici.   
 
D’altro canto, l’analisi immunoistochimica del Fattore VIII, con proprietà 
pro-coagulanti,  ha rivelato che questa proteina endoteliale è presente in 
maniera continua e costante lungo il lumen della vena porta e della vena 
cava sia nei pazienti cirrotici che non. La diminuzione della 
trombomodulina può dannegiare le proprietà anticoagulanti dell’endotelio 
che, in presenza del Fattore VIII preservato, può portare allo sviluppo della  
trombosi.  
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La trombosi della vena porta rappresenta una complicanza rilevante nella 
storia naturale dei pazienti cirrotici, causando frequentemente un aumento 
della morbilità prima e della mortalità dopo il trapianto epatico.  
 
L’ottenimento della ricanalizzazione tramite terapia anticoagulante è 
perciò importante, e nel presente studio è stata fatta un’analisi dei fattori 
che possono avere un impatto sull’efficacia della terapia con eparina a 
basso peso molecolare in pazienti cirrotici con questa complicanza.  Si è 
dimostrato che l’anticoagulazione con eparina a basso peso molecolare è 
una strategia valida per la ricanalizzazione della vena porta, con un tasso 
di risposta del 65.2%, includendo ripermeazione completa in 24 dei 46 
pazienti trattati, dopo una media di 4.5 mesi (±3.1 mesi) di 
anticoagulazione.  Nonostante lo status emostatico dei pazienti non 
correlava con la risposta all’anticoagulazione, l’intervallo tra lo sviluppo del 
trombo e l’inizio della terapia è stato l’unico fattore predittivo dell’efficacia 
terapeutica.  Specificamente, l’età del trombo alla diagnosi (1.9 ± 1.2 mesi 
vs 6.3 ± 4.5 mesi, rispettivamente, p<.001) e l’intervallo tra lo sviluppo del 
trombo e l’inizio della terapia anticoagulante (3.2 ± 1.7 mesi vs 7.78 ± 4.5 
mesi nel gruppo che ha ottenuto ricanalizzazione e nel gruppo che non ha 
ottenuto ricanalizzazione, rispettivamente, p<.002) sono stati i principali 
determinanti dell’efficacia terapeutica.  Questo sottolinea l’importanza di 
una diagnosi precoce e di un opportuno inizio della terapia, per 
incrementare la probabilità di successo del trattamento anticoagulante.  
Benché i livelli bassi di antitrombina, necessaria per l’azione dell’eparina,  
verificatesi in cirrosi possano teoricamente diminuire l’effetto 
anticoagulante, in questo studio si è dimostrata l’efficacia clinica 
dell’anticoagulazione con eparina a basso peso molecolare.  
 
L’effetto anticoagulante dell’eparina a basso peso molecolare è stato 
esplorato in vitro utilizzando il test della trombino generazione, e 
concentrazioni di eparina dentro il range  terapeutico sono state in grado 
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di ridurre la generazione della trombina, nonostante la spiccata riduzione 
nei livelli plasmatici di antitrombina e i bassi livelli di anti-Xa determinati in 
vitro.  In particolare, i pazienti in classe C di Child Pugh si sono 
caratterizzati da livelli di antitrombina bassi quanto quelli presenti in 
pazienti con la condizione protrombotica di deficit genetico di questa 
proteina (42±14% vs 52±4%, rispettivamente,  p=.06). Alla concentrazione 
in vitro di 0.35 UI/mL di eparina a basso peso molecolare, l’attività anti-Xa 
è stata significativamente più bassa in pazienti in classi di Child Pugh B e 
C rispetto ai controlli (p<.001), così come in pazienti con difetto genetico 
dell’antitrombina rispetto ai controlli (p<.001).  Nonostante i ridotti livelli di 
attività anti-Xa, i pazienti cirrotici hanno dimostrato un maggiore effetto 
anticoagulante dell’eparina a basso peso molecolare, con una riduzione 
del potenziale endogeno di trombina di 72.6±11% (p=0.02 vs i controlli). 
Data l’incrementata suscettibilità dei pazienti cirrotici in stadi avanzati della 
malattia epatica, potrebbe essere necessaria la riduzione della dose di 
anticoagulazione.  
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Multiple changes occur in the hemostatic system as a result of deranged 
liver function. Being the liver the primary site of synthesis of most 
coagulation factors, as well as of proteins which keep these mechanisms 
in check, severe derangement of its function has long been known to 
result in bleeding complications such as epistaxis, gastrointestinal 
bleeding from esophago-gastric varices, and gum bleeding, but also in 
thrombotic complications.  
 
Routinely performed coagulation profile is abnormal in the majority of 
these patients, and clinical consequences of alterations in this complex 
interplay  may lead to bleeding or to thrombosis.  In patients with severe 
liver disease, hemostasis is affected due to diminished synthesis of factors 
II, V, VI, IX, X, XI, XIII, fibrinogen, protein C, protein S, oftentimes 
coexisting with Vitamin K deficiency due to malabsorption or malnutrition.  
Dysfibrinogenemia, enhanced fibrinolysis, impaired clearance of activated 
clotting factors, plasminogen activators, and fibrinogen degradation 
products all contribute to altered hemostasis in cirrhosis. Coagulation in 
patients with decompensated liver cirrhosis can also be affected by other 
factors like infections, endogenous heparinoids, renal failure, and 
endothelial dysfunction(1-3).    
 
 
Procoagulant factors 
 
While von Willebrand factor is synthesized by the endothelium (4) and 
Factor VIII is primarily synthesized by hepatic sinusoidal cells(5;6), the 
liver is the site of synthesis of fibrinogen and factors II, V, VII, IX, X, XI and 
XII (7). Thus the plasma concentration of factor VIII is not decreased with 
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liver disease, and may be even increased, as many chronic liver diseases 
are associated with chronic inflammation (8). This probably obeys to an 
increase in endothelial synthesis, a reduced clearance via low-density 
lipoprotein receptor-related protein (4), and increased levels of von 
Willebrand factor. However, the biological activity of the synthetized 
molecule is lower than the plasmatic concentration (9). Furthermore, 
Factor VIII is elevated in fulminant hepatic failure but decreased in 
disseminated intravascular coagulation (DIC) (10).  
 
Vitamin K is an essential cofactor for the production of biologically active 
forms of the coagulation factors II, VII, IX and X, enhancing hepatic post-
ribosomal conversion of certain glutamic acid residues in the protein 
precursors, to -carboxyglutamic acid (Gla). These active forms of the 
clotting factors chelate calcium at the Gla site, resulting in effective 
hemostatic function. When -carboxylation is impaired due to deficiency or 
antagonism of vitamin K, inert precursors are synthetized, (known as 
Proteins Induced by Vitamin K Absence [PIVKA]) and released into the 
blood stream (11). The clinical significance of these precursors is not 
clear. In the case of prothrombin, a specific and sensitive immunoassay 
has been developed which is able to detect small decreases in Gla 
content of this incomplete PIVKA prothrombin before any changes occur in 
conventional coagulation tests (12). In cholestasis, reduction of vitamin K 
absorption from the small intestine due to decreased bile salt production 
can be compensated with parenteral administration of vitamin K 10mg 
daily for 24-48 hours, but in parenchymal liver disease decreased levels of 
coagulation factors are dependent on a decreased synthesis, so that there 
is no improvement with vitamin K administration (13). Nevertheless 25% of 
patients with acute liver injury have a subclinical deficit of vitamin K which 
may benefit from parenteral administration, with corresponding 
improvement of the INR (14). 
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Anticoagulant Factors 
 
Antithrombin III (ATIII) is a non-vitamin K-dependent glycoprotein 
synthesised by the liver but also by the endothelium (15). It has low 
concentration in patients with liver disease, probably due to reduced 
synthesis and/or increased consumption due to hyperfibrinolysis (16). 
ATIII replacement does not correct hyperfibrinolysis in patients with liver 
cirrhosis. Usually the ATIII deficit is mild and thrombosis as a complication 
is very rare, reported only sporadically (17).  
 
Proteins C and S are vitamin K dependent glycoproteins synthesised 
mainly by hepatocytes (18). Therefore during acute or chronic liver 
disease, their concentrations can be decreased concomitantly with the 
other coagulation factors, but usually not below 20% of normal values 
(19). Genetic deficiency of protein C is rare in the general population, but 
found in 20% patients with Budd-Chiari syndrome (BCS). In patients with 
liver disease who also have genetic deficiency, plasma concentration is 
often lower than 20%. When there is severe liver disease, it can be difficult 
to exclude coexistent genetic deficiency as levels may be very low, due to 
very depressed synthesis (20).  In this situation a concomitant finding of a 
normal level of factor II and protein C/factor VII ratio, can help to confirm a 
coexistent genetic deficit (21). In acquired deficiency of vitamin K, a 
defective protein C lacking -carboxyl (PIVKA) is produced (22). Protein C 
deficiency is not associated with extrahepatic portal vein thrombosis (23). 
Genetic deficiency of protein S is extremely rare, yet accounts up to 7% of 
patients with BCS or portal vein thrombosis (PVT), especially in series 
from Asia (24).  
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Overview of hemostasis alterations in cirrhosis 
The fact that a rebalanced hemostatic status, which can be easily tipped 
towards bleeding or towards thrombotic complications not only is evident 
from laboratory studies, but also from the clinical point of view.  It is ever 
clearer that patients with cirrhosis are not “auto-anticoagulated”, as 
previously thought, but actually have a greater risk than non-cirrhotic 
counterparts for developing thrombotic complications as well. Clinically, 
evidence is accumulating regarding a relative hypercoagulable state which 
is present in patients with cirrhosis. (Table 1). 
 
Table 1. Evidence of thrombotic complications in patients with liver 
disease (25). 
 
Disease state Possible contributing etiologies 
Portal vein thrombosis Obstruction of flow 
Prothrombotic predisposition 
Infectious nidus from gastrointestinal tract 
Local inflammatory mediators 
Deep vein thrombosis or 
pulmonary embolism 
Imbalance in clotting cascade favoring 
coagulation 
Immobility of end-stage liver disease 
Infection and systemic inflammation 
Progression of cirrhosis Parenchymal extinction 
Vascular prosthesis and 
extracorporeal circuit 
thrombosis 
Mechanical obstruction 
Inflammatory mediators 
Abnormal platelet adhesion 
Portopulmonary 
hypertension 
Pulmonary endothelial dysfunction 
Microvascular pulmonary thrombosis 
Altered shear stress in the pulmonary 
vessels 
Metabolic syndrome and 
non-alcoholic fatty liver 
disease 
Venulitis and microthrombi with remodeling 
Atherosclerotic  vascular changes 
Inflammation related to metabolic syndrome 
Factor level alteration with insulin resistance 
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From the point of view of laboratory parameters, patients with chronic or 
acute liver failure show profound abnormalities in their haemostatic and 
coagulation system(2;26).   
 
Despite routine coagulation tests may be compatible with a bleeding 
tendency, both pro and anti-coagulation factors are affected, the latter of 
which are not well reflected in these tests (27). Reduced levels of FII, FIX, 
FXI, FXII are characteristic of the coagulation profile of a typical patient 
with cirrhosis, and levels are correlated to the severity of liver disease.  
However, anticoagulant factors are also decreased in cirrhosis, and 
therefore a new thrombotic-hemostatic balance is reached(2;28).  
 
In fact, more global tests such as thrombin generation test (TG), which are 
able to detect the overall effect of deficient anticoagulant mechanisms in 
plasma of cirrhosis patients, have shown that endogenous thrombin 
potential in cirrhosis patients is not significantly different from that of 
healthy subjects(29).  Specifically, when the thrombin generation test is 
performed in the presence of thrombomodulin, an endothelial receptor 
which catalyzes the thrombin-mediated conversion of Protein C into its 
active form activated Protein C, the amount of thrombin generated is 
similar between plasma from cirrhotic and from healthy subjects(30;31).  
 
As mentioned above, aside from acquired coagulation-hemostatic defects, 
it has been demonstrated that genetic thrombophilias are more frequent in 
cirrhosis patients with PVT when compared to cirrhosis patients without 
PVT.  In a study by Amitrano et al, the frequencies of Factor V Leiden and 
of Prothrombin A20210 polymorphism were reportedly 13% and 34.8% in 
cirrhotic patients with PVT, whereas frequencies were 7.5% and 2.5% in 
cirrhotic patients without PVT (32).   
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Regarding primary hemostasis, chronic liver disease is characterized by a 
variable degree of thrombocytopenia due to increased platelet destruction, 
increased splenic and/or hepatic sequestration, or to reduced levels of 
thrombopoietin and by altered platelet function due to defective 
thromboxane A2 synthesis, storage pool deficiency and abnormalities of 
the platelet glycoprotein Ib (33-39).     
 
Different mechanisms compensate for reduced platelet number and 
function: von Willebrand factor is notably elevated in cirrhosis, probably as 
a result of its reduced clearance resulting from diminished levels of its 
cleaver ADAMTS13 and as a reflection of high levels of FVIII, to which it is 
bound when circulating in plasma(40).  A summary of these alterations in 
the hemostatic-thrombotic systems is presented on table 2.  
 
Table 2. Alterations in the hemostatic system in patients with liver 
disease that contribute to bleeding (left) or counteract bleeding 
(right)(27). 
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Thrombin generation  
 
Thrombin is often seen as the end-product of the coagulation cascade and 
as such responsible for the final step, the conversion of the soluble protein 
fibrinogen into the insoluble fibrin clot. However, the coagulation cascade 
is actually composed of many feedback loops and inhibitory pathways that 
are all directly or indirectly influenced by the developing thrombin 
concentration, which renders thrombin pivotal throughout the entire 
coagulation-anticoagulation process.  
 
The thrombin generation assay in plasma is a test which assesses 
coagulation globally, and is able to detect alterations both in coagulation 
and anticoagulation mechanisms (41) (Figure 1). In contrast to 
determination of thrombin generation in vivo, which detects byproducts of 
an ongoing thrombus formation such as prothrombin fragments 1-2 and d-
dimer, the thrombin generation assay measures ex vivo the potential 
capacity of a certain sample to generate thrombin, triggered by tissue 
factor.  The sample analyzed may be platelet-poor plasma (PPP), or 
platelet-rich plasma (PRP), and the interplay between all coagulation 
components is analyzed concomitantly, with the exception of the vessel 
wall.  To this end, thrombomodulin and tissue factor are added to the 
assay, rendering the test a very close approximation to what occurs inside 
the vessel. Phospholipids are added as platelet substitutes when PPP is 
analyzed, providing a pro-coagulant surface.  This method can monitor the 
initiation, propagation and decay phases of thrombin generation. In 
addition, this assay also measures the endogenous thrombin potential 
(ETP), which represents the activity of thrombin multiplied by the time for 
which it remains active in plasma(42).  
 
Thrombin generated from the plasma sample after addition of a suitable 
trigger (tissue factor, recalcification of thawed plasma), is measured using 
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a fluorogenic substrate.  The amount of generated thrombin is plotted 
against time to construct a thrombin generation curve (or thrombogram) 
(Figure 2).  A computer program developed by Hemker and collaborators 
calculates the parameters which characterize the thrombogram i.e., the 
lag time, the peak height, the time to peak and the endogenous thrombin 
potential (ETP) (Figure 3) (43).  The latter is the area under the thrombin 
generation curve and represents the total amount of thrombin formed over 
time, after exclusion of the contribution to amidolysis of the 
alpha2macroglobulin-thrombin complex that is unable to convert fibrinogen 
into fibrin, but retains amidolytic activity towards the thrombin-specific 
synthetic substrates. The fluorescent signal has the drawback of not being 
linear with product concentration(44). To compensate for this and for the 
effects of substrate consumption, the calibrated automated thrombogram 
(CAT) method has been developed, which continuously compares the 
signal from the experimental sample to that of a fixed known thrombin 
activity (45). This method allows visualizing the thrombin concentration in 
clotting PPP or PRP in 24 parallel experiments.   In the present study, the 
Thrombinoscope™ software (Thrombinoscope BV) was used, together 
with the Thrombinograph™, a 96-well plate fluorimeter (Thermo Scientific).  
A thrombin calibrator was used for every sample, to correct for the inner 
filter effect, donor-to-donor variability in color of plasma, substrate 
depletion and instrumental differences.  
 
The study of thrombin generation – performed either with clotting-based 
assays, or with chromogenic substrates – is an established tool in blood 
coagulation research –(43;46-49). It has been shown that the thrombin 
generation assay is able to detect thrombophilic phenotypes in subjects at 
risk of VTE (50-52).  When this test is performed in the presence of 
thrombomodulin or activated protein C, alterations in the pathway of the 
natural anticoagulant protein C are unmasked.  
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In population-based studies Lutsey et al. demonstrated an increased risk 
for VTE (primarily idiopathic) for elevated peak values of TG (53).  
Furthermore, Tripodi and colleagues demonstrated a correlation between 
TG values and clinical risk assessment of VTE (low, medium, high risk of 
VTE), when thrombin generation assay was performed in the presence of 
thrombomodulin(54).  In cirrhosis patients, studies performed using the 
thrombin generation assay have demonstrated an imbalance between pro- 
and anti-coagulant factors which tends towards hypercoagulability and is 
unveiled by the addition of thrombomodulin(55). Finally, the thrombin 
generation test has also been used to study the anticoagulant effect of 
multiple anticoagulant drugs, showing adequate sensibility to detecting 
their action (56).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Calibrated automated thrombogram system (CAT) by 
Thermo Electron. The instrument consists of  a 96-well microplate 
fluorometer and Thrombinoscope™ package. 
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Figure 2. Typical thrombin generation curve (thrombogram). 
The endogenous thrombin potential (ETP) corresponds to the area under 
the curve. 
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Figure 3. Thrombin generation curve and parameters. 
Thrombin generated and subsequently degraded is plotted against time. 
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Clinical evidence of pro-thrombotic complications in cirrhosis  
 
Venous thromboembolism 
 
Patients with cirrhosis appear to have a higher incidence of unprovoked 
deep vein thrombosis and pulmonary embolism (DVT/PE) compared with 
the general population. Although there are no prospective studies that 
report on the incidence of venous thromboembolism (VTE) in patients with 
cirrhosis, a nationwide population-based study undertaken in Denmark 
evaluating more than 99000 patients with thromboembolism showed that 
cirrhosis and liver disease carry a greater risk of VTE (OR of 2.10, and of 
3.58 if age < 55 years)(57). In a prospective cohort study with case-control 
analysis of 6550 patients with VTE in the United Kingdom, Huerta et al. 
found that in patients with chronic liver diseases, the odds ratio for PE was 
1.75 (CI 0.91–3.36), and the odds ratio for DVT/PE combined was 1.65 (CI 
0.97–2.82), demonstrating not only that these patients are not protected 
from thromboembolic events, but rather that cirrhosis is a predisposing 
condition(58).   
 
Eight articles, of which two are case-control studies and six are 
retrospective studies, have been published up to date specifically aimed at 
investigating the incidence of DVT and PE in patients with cirrhosis (59-
66). (Table 3)  
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Table 3. Prevalence of venous thromboembolism in patients with 
cirrhosis admitted for hospitalization (59-66). 
 
Reference Type of study 
Study 
population (n) 
Incidence of 
DVT/PE (%) 
DVT 
number (%) 
PE 
number (%) 
DVT+PE 
number (%) 
Northup et al. (2006) Case control 21000 113 (0.5%) 74 (65.5%) 22 (19.5%) 17 (15%) 
Garcia Fuster et al. (2008) Retrospective 2074 17 (0.8%) 10 (59%) 6 (35%) 1 (6%) 
Gulley et al. (2008) Case control 963 18 (1.87%) NA NA NA 
Lesmana et al. (2010) Retrospective 256 12 (4.7%) 12 (100) 0 (0%) 0 (0%) 
Ali et al.(2010)  Retrospective 449798 8231 (1.8%) 4335 (0.9%) 3688 (0.8%) 208 (0,8%) 
Dabbagh et al.(2010) Retrospective 190 12 (6.3%) NA NA NA 
Wu et al. (2010) Retrospective 649879 52881 (8.1) NA NA NA 
Aldawood et al. (2011) Retrospective 226 6 (2.7%) 6 (100%) 0 (0%) 0 (0%) 
 
DVT: Deep vein thrombosis; NA: data not available; PE: pulmonary embolism. 
Adapted from(67).  
 
 
 
Portal vein thrombosis 
 
The portal vein is certainly the most common site for thrombus formation in 
patients with advanced liver disease.  Moreover, non-neoplastic portal vein 
thrombosis (PVT) is more frequent in cirrhosis than in the general 
population, with a prevalence of 0.6 to 26% in patients without 
hepatocellular carcinoma, although the wide range in reported prevalence 
is owed to the different groups of cirrhotic patients studied and the 
different diagnostic method (68-74).       
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Risk factors for the development of portal vein thrombosis in 
cirrhosis 
 
The occurrence of pathological thrombosis is determined by an alteration 
in the physiological equilibrium that regulates coagulation and 
anticoagulation dynamics, and shifts regarding any one of the components 
of Virchow’s triad (venous stasis, endothelial injury and 
hypercoagulatiblity) may result in thrombosis. Both local and systemic 
factors can result in the development of site-specific thrombosis, 
particularly PVT.  
 
In patients with end-stage liver disease, venous stasis results from 
splanchnic vasodilatation and architectural derangement, which primarily 
involves the cirrhotic liver. In one prospective study regarding a cohort of 
73 patients with cirrhosis, reduced portal flow velocity below 15 cm/s was 
the only independent variable that correlated with the risk of developing 
PVT at 1 year of follow-up(75).   However, the prospective study by 
Francoz et al. on 251 patients with cirrhosis listed for liver transplantation 
failed to find a correlation between portal flow direction (hepatofugal or 
hepatopetal) and risk of development of PVT(70).  Recent in vivo evidence 
shows that the ratio of the most important pro and anticoagulant factors, 
factor VIII and protein C, respectively, demonstrates a strong imbalance in 
favor of factor VIII in cirrhotics, indicating a hypercoagulable state(55).  
 
In several series, elevated levels of factor VIII have been shown to be a 
risk factor associated with either primary or cirrhosis-associated 
PVT(76;77). This has been confirmed in a larger cohort that evaluated 58 
non-cirrhotic patients with PVT, 27 cirrhosis patients with PVT and 200 
with DVT, in whom a strong association between elevated levels of FVIII 
and the risk of PVT was demonstrated (odds ratio for thrombosis and fVIII 
levels above 129 UI/dl being 6.0 for cirrhosis)(78). 
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The possible role of inherited thrombophilic abnormalities has been 
advocated in several cross-sectional studies reporting a thrombophilic 
genotype in up to 9% of patients with cirrhosis and PVT. It has also been 
demonstrated that polymorphisms TT677 of methylene-trahydrofolate 
reductase, and G20210A in the prothrombin gene are significantly more 
frequent in this group than in controls(32;68;71). Although not 
demonstrated in all studies regarding the liver transplant population(79), in 
other studies, the risk of PVT has been shown to be independently 
associated with the severity of  cirrhosis, being paradoxically more 
frequent in those patients with worsening indices of coagulation and those 
with worsening portal hypertension (i.e. ascites and 
encephalopathy)(73;80).  
 
Furthermore, PVT is more likely to occur in late stages of cirrhosis, and the 
combination of sclerotherapy and history of abdominal surgery are 
associated with an increased risk of PVT, which is probably not the case 
of a causal relationship, but rather reflecting a more advanced disease 
stage (68).  The presence of previous treatments for portal hypertension 
(sclerotherapy, TIPS, shunt surgery, previous splenectomy) and severity of 
liver disease classified as Child Pugh C are two factors which have been 
found to be significantly associated with an increased risk of PVT (73), and 
the former was also demonstrated in other  studies analyzing risk factors 
for PVT in liver transplantation  series(74;81).  
 
Table 4 summarizes the most important reported risk factors for the 
development of PVT in patients who undergo liver transplantation 
(70;73;74;79;80;82-89).  
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Table 4. Risk factors for non-neoplastic portal vein thrombosis (PVT) 
in liver transplant (LT) candidates (70;73;74;79;80;82-89). 
 
Study, year Statistically associated risk factors Investigated risk factors with no 
demonstrated association 
Cherqui, 1993     Child Pugh classification, presence of 
ascites, previous variceal bleeding, number 
of endoscopic sclerotherapies 
Ravaioli, 2011    Hepatic neoplasm (40.7% vs no neoplasm 30.7, 
p=0.05) 
Alcoholic cirrhosis (23.3% vs other etiology of 
cirrhosis 10.9%, p<.001) 
Age, sex, presence of TIPS 
Nonami, 1992  Postnecrotic cirrhosis (Alcoholic, viral, 
autoimmune, drug-induced, cryptogenic) 
Hepatic neoplasm (34.8% vs no neoplasm 11.4, 
p<.001) 
Portal hypertension, previous treatment for portal 
hypertension (TIPS) 
Primary biliary cirrhosis, Primary sclerosing 
cholangitis, liver-based inborn errors of 
metabolism, biliary atresia.  
Davidson, 1994 Autoimmune hepatitis (60% vs 8.6%, p<.03) 
Cryptogenic cirrhosis ( 33%  vs 8.3%, p<.05) 
Hepatic neoplasm (27% vs 9%, p<.05) 
 
 
Gayowski, 1996    Etiology of liver disease, age, sex, Child 
Pugh classification, previous abdominal 
surgery, liver size 
Yerdel, 2000 Male sex, previous treatment for portal 
hypertension (sclerotherapy, TIPS, shunt surgery, 
previous splenectomy), Child C classification, 
Alcoholic liver disease. The presence of any one 
of these factors was associated with a rate of 
PVT of 12.5% (vs 6.6% if none of these risk 
factors was present), p<.013 
Age, previous upper abdominal surgery, 
hepatic neoplasm 
Manzanet, 2001    Hepatic neoplasm, primary biliary cirrhosis 
Francoz, 2005        Platelet count MELD score 
Direction of portal vein flow 
Past medical history of variceal bleeding 
(47.4% vs 29.1%, p=.162) 
Gimeno,2005   Primary and secondary biliary cirrhosis 
Egawa, 2006  MELD in PVT patients was lower (mean 18.2) vs 
in non-PVT patients (mean 21.9), p=.0106 
 
Lladó, 2007   Age, sex, severity of liver disease (Child 
class), previous TIPS 
Pan, 2009  Male sex (11.05% male vs 4.23% female, p<.01) 
Previous splenectomy (27.4% vs 8.7% without 
previous splenectomy, p<.01) 
 
Englesbe, 2010 MELD at transplant 21.8±8.7 in PVT patients vs 
20.9±9 in non-PVT patients, p=.0044 
Diabetes: 26.1% of PVT patients vs 21.4% in 
non-PVT patients, p=.0008 
Age at transplant: PVT patients were 54±9 years 
old vs non-PVT patients 52.8±9.5, p=.0002 
Previous abdominal surgery: 51.7% of PVT 
patients vs 42.8% in non-PVT, p<.0001 
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Endothelial injury and development of portal vein thrombosis 
 
Endothelial alterations of the portal vein in cirrhosis patients which can 
compromise natural antithrombotic mechanisms, together with the 
hemostatic plasmatic alterations as well as venous stasis, may play a key 
role in development of site-specific thrombosis of the portal vein. 
 
Cirrhosis is being increasingly recognized as a condition characterized by 
vascular damage, which can result in significant impairment of the 
physiologic mechanisms that ensure vessel permeability and the myriad of 
its homeostatic functions (90). A generalized inflammatory state is 
perpetuated by altered substance hepatic metabolism, shear stress due to 
disturbed hemodynamics and volume distribution, and the presence of 
circulating bacterial products caused by bacterial translocation from the 
gut.  
Evidence of altered vascular permeability has been demonstrated in 
animal models of cirrhosis and more recently in cirrhosis patients (91). 
Moreover, proteins and glycoproteins associated with endothelial injury 
and inflammation, such as heparin-like substances, are notably elevated in 
cirrhosis. There is evidence that cirrhosis -and its possible concomitant 
events such as bacterial translocation, portal hypertension, and ascites -
determines a particular set of conditions that challenge the endothelium’s 
physiologic anti-thrombotic and anticoagulant capacity. 
Furthermore, there is evidence to support the concept of greater 
inflammation and endothelial injury within the portal vein with respect to 
other venous beds in cirrhosis patients(91). D-dimer, an established 
marker of inflammation, which is also associated with abnormal activation 
of the coagulation cascade, has been demonstrated to reach significantly 
higher levels in blood samples drawn from the portal vein when compared 
to levels in blood samples from the jugular vein of cirrhosis patients (92). A 
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similar pattern has also been demonstrated for levels of prothrombin F1+2, 
demonstrating significantly higher levels in the portal vein vs the jugular 
vein, which represents systemic venous blood  (92). Moreover, elevated 
levels of glycosaminoglycans, constituents of the glycocalyx, are elevated 
in patients undergoing liver transplant for advanced cirrhosis, and probably 
reflect shedding from an injured endothelium (3).  
 
Regarding the endothelial anticoagulant mechanisms, a fundamental role 
is played by thrombomodulin. This cell surface-expressed transmembrane 
glycoprotein, predominantly synthesized by vascular endothelial cells, is a 
critical cofactor for thrombin-mediated activation of protein C, an event 
further amplified by the endothelial protein C receptor, as part of the 
natural anticoagulant mechanisms. This protein, which is present in both 
large vessels and capillary endothelium, and has a crucial role in 
anticoagulation, has also been implicated in inflammation (93).  In fact, this 
protein has also been studied with regard to endothelial injury, linking both 
inflammation and coagulation, conditions that present concomitantly in 
cirrhosis. This  endothelial cell surface glycoprotein forms a 1:1 complex 
with thrombin, and this binding activates protein C approximately 1000x 
faster than thrombin alone.  Activated protein C, in turn, together with 
Protein S, inactivates Factor Va and VIIIa.  TM also modulates 
inflammation independently of activated protein C, by activating anti-
inflammatory pathways, negatively regulating complement, and by 
facilitating the activation of tissue activatable fibrinolysis inhibitor (TAFI), 
which modulates both fibrinolysis and complement-mediated inflammation 
(94-97).   
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Clinical consequences of portal vein thrombosis in cirrhosis and 
rationale for treatment 
 
Clinical manifestations of PVT vary from asymptomatic disease to a life 
threatening complication. In a study on 79 cirrhotic patients with newly 
diagnosed PVT, 39% presented with gastrointestinal bleeding (from 
varices or portal hypertensive gastropathy) and 18% had abdominal pain, 
amongst which 70%  had intestinal infarction due to the extension of the 
thrombus into the mesenteric vein (71).  
 
PVT may worsen portal hypertension and may lead to variceal bleeding, 
development or worsening of preexisting ascites, and increases mortality 
and morbidity after liver transplantation. As emerged from a recently 
published systematic review, the presence of non-neoplastic PVT at LT 
entails a greater 30-day mortality after surgery when compared to patients 
without PVT (10.5% vs 7.7%, respectively (p=.01)(98). One-year mortality 
is also increased in patients who undergo LT in the presence of PVT in 
contrast with those with patent portal vein at transplant (18.8% vs 15.3%, 
respectively (p<.001). Furthermore, the presence of complete or Grade IV 
PVT according to Yerdel adversely affects outcome after liver 
transplantation, as shown in table 5.           
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Table 5. Early (30-day) mortality and 1-yr mortality in patients according to 
the grade of portal vein thrombosis (PVT) in liver transplant (LT) recipients 
with this complication (73;83;84;86;88;89;99-104). 
 
Author, year of 
publication 
LT 
recipients 
n  
30-day mortality 
Number of patients (%) 
1 year mortality  
Number of patients (%) 
Partial PVT Complete PVT Partial PVT Complete PVT 
Ravaioli (2011)  91 1/50 (2) 5/41(12.2) - - 
Suárez (2010)  48 - - 5/28 (17.8) 9/20 (45) 
Egawa (2006)  39 5/29 (17.2) 6/10 (60) - - 
Azoulay (2002)  8 - 0/8 (0) - - 
Manzanet (2001)  62 2/48 (4.2) 2/14 (14.3) 12/48 (25) 5/14 (35.7) 
Davidson (1994)  14 0/7 (0) 1/7 (14.3) - - 
 
30-day mortality 
Number of patients (%) 
1 year mortality  
Number of patients (%) 
G I G II G III G IV G I - G II G III - G IV 
Yerdel (2000)  63 3/24 (12.5) 8/23 (34.8) 2/6 (33) 5/10 (50) 
 
Pan (2009)   253 0/218 (0) 1/29 (3.4) 2/6 (33.3) 
Ceulemans (2005)  5 
 
0/5 (0) 
Urbani (2002)  6 1/6 (16.7) 
Olausson (2001)  6 1/6 (16.7) 
Doenecke (2010)  193  2/13 (15.4) 5/11 (45.5) 
G = grade; LT= liver transplant; PVT = Portal vein thrombosis 
                                                                                                                                    
  
Although no longer considered an absolute contraindication for liver 
transplantation (LT), occlusive PVT still precludes LT in many centers and  
increases the complexity of LT(81;105;106).   In PVT patients undergoing 
LT, operative time, rate of reoperation or postoperative complications, 
transfusion requirement, and length of hospital stay are increased(73), 
while survival rates, related to the extent of thrombosis, are decreased(70). 
Whereas terminal to terminal portal vein anastomosis, with or without low 
dissection, thrombectomy, and/or thrombendvenectomy can be  
appropriate for isolated PVT, more complex vascular reconstruction 
techniques are required when the thrombus extends into the superior 
mesenteric vein. Porta-cava hemitransposition is the most common option 
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during transplantation with PVT extending into the superior mesenteric 
vein(107), but is characterized by survival of 60% and 38% at 1 and 3 
years, respectively, and entails a 30% bleeding complications related to 
residual portal hypertension after transplantation(108).  
 
These recent studies underscore the need for a clear protocol for the 
treatment of PVT  in  patients with cirrhosis, regardless of whether LT 
might be a future prospect or not.  
 
Hence, the aims of PVT management in patients with cirrhosis  listed for 
LT are the achievement of complete or partial recanalization and the 
prevention of  thrombosis progression. These goals can be achieved 
either through the placement of, a transjugular  intrahepatic portosystemic 
shunt (TIPS), with or without local thrombolysis or thrombectomy(109;110) 
or employing anticoagulation(111). 
 
The rationale for the use of anticoagulation to treat PVT in patients with 
underlying liver disease derives from larger experiences published in 
patients with PVT and no liver disease, and the rare event of spontaneous 
recanalization (112;113). In patients with non-cirrhotic PVT,  recanalization 
rate is achieved in 40%  of  patients who receive early 
anticoagulation(112;114;115). Since recanalization has been shown to 
occur only within 6 months from the start of anticoagulation, the duration of 
anticoagulation is currently recommended for at least 3 and preferably for 
up to 6 months(112;114). Evidence for the use of anticoagulation to treat 
PVT in patients with  cirrhosis  is more scarce.  
 
The development of thrombotic complications in cirrhosis patients warrants 
a therapeutic approach that is similar to the non-cirrhosis setting.  
However, the anticoagulant of choice is still not known and a suboptimal 
utilization of prophylactic fractionated heparin in cirrhotic patients has been 
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recently described(65).  Several low-molecular-weight heparins (LMWHs) 
are currently available as anticoagulant drugs for the prophylaxis and 
treatment of thrombosis in non-cirrhotic patients. LWMHs act by 
stimulating antithrombin (AT)-mediated inhibition of factor Xa;  those with 
saccharide chains above a critical length also exert  an inhibitory effect on  
thrombin. Due to their pharmacokinetic properties, LMWHs have a much 
more predictable anticoagulant effect than unfractionated heparin. (Figure 
4) This allows for monitoring of clotting times to be avoided and makes it 
possible to   use weight-adjusted or fixed doses of LWMHs depending on 
the clinical setting.  Since LMWHs exert their anticoagulant effect by 
means of AT, the reduction of plasmatic levels of this protein seen in 
patients with advanced liver disease could theoretically hamper its  
anticoagulant effect. 
 
Recently, Bechmann et al have demonstrated that after administration of 
LWMH, cirrhotic patients reach lower levels of anti-Xa activity than 
controls, which correlate to the severity of liver disease(116).  Although 
this finding could also suggest the need to increase the dose of LWMH in 
cirrhotics, Lisman and colleagues showed in vitro that the anti-Xa assay 
underestimates LWMH plasma levels in patients with cirrhosis(117;118).  
 
Low molecular weight heparin (LMWH) has been shown to be effective for 
the treatment of PVT in 45-75% of patients; however it is still not clear 
which thrombus and patient characteristics, including hemostatic 
coagulation balance, are predictive of the response to anticoagulation 
therapy.  
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Figure 4. Action site of unfractioned heparin, low molecular weight 
heparin and fondaparinux. 
 
Source: Am J Health-Syst Pharm © 2002 American Society of Health-
System Pharmacists 
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Project I: Endothelial dysfunction in cirrhosis: 
characterization of structural and functional aspects of the 
portal vein which lead to in situ thrombosis.  
1. To analyze the integrity of the endothelial lining in cirrhotic patients 
using specific markers for endothelial cells, such as FVIII, and to 
compare it to that of other systemic venous territories, as 
exemplified by the vena cava, and to compare these findings to 
those of the portal vein and vena cava of non-cirrhotic subjects.  
 
2. To study the anticoagulant properties of the endothelium as 
represented by the distribution of thrombomodulin, the main 
endothelial anticoagulant protein, in the portal vein and vena cava 
of cirrhotic subjects and compare it to that of non-cirrhotic subjects.      
 
 
 
Project II: Predictors of response to anticoagulant therapy in 
cirrhosis patients with portal vein thrombosis.  
3. To assess hemostatic status in terms of pro- and anti-coagulant 
factors, as well as clinical characteristics of the thrombus and 
patients, as predictors of therapeutic efficacy of anticoagulation with 
low molecular weight heparin to treat portal vein thrombosis in 
patients with cirrhosis. 
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Project III: Anticoagulant response to low molecular weight 
heparin in plasma from patients with advanced cirrhosis.  
4. To evaluate the effect of low molecular weight heparin on 
endogenous thrombin potential in plasma from patients with 
cirrhosis.  
 
5. To correlate  the anticoagulant efficacy of low molecular weight 
through thrombin generation assay with levels of anti-Factor Xa 
(activated Factor X) in plasma from patients with cirrhosis.  
 
6. To correlate the anticoagulant effect of low molecular weight 
heparin in vitro with the severity of liver disease.  
 
7. To correlate the efficacy of low molecular weight heparin in vitro 
with the determined plasmatic levels of coagulation factors and 
antithrombin in plasma from patients with cirrhosis.  
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Materials and Methods 
 
Venous samples 
 
Venous samples from vena cava and portal vein were from obtained from 
adult subjects at transplant surgery in the case of cirrhosis patients, and 
during organ retrieval in non-cirrhosis donors (controls). All procedures 
were performed according to the Helsinki declaration. Criteria for exclusion 
of patients were: hepatocellular carcinoma (HCC), fulminant or acute 
hepatic failure, extrahepatic neoplasms, known genetic or acquired 
thrombophilia or overt thrombotic complications (DVT, PVT, or VTE) 
subsequently confirmed by determination of prothrombotic mutations 
(Factor V Leiden, prothrombin polymorphism G20210A) and pediatric LT 
recipients (<18 years of age).  Criteria for exclusion of controls were 
similar to criteria used to exclude potential donors (neoplasm, abdominal 
trauma). As part of the protocol for organ retrieval, visual assessment by 
the surgeon and histological intraoperative analysis exclude the presence 
of significant liver disease.     
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Sample obtainment  
 
Upon notice from the on-call transplant coordinator, the equipment 
necessary for sample transportation and preservation was prepared.  
Vena cava and portal vein samples were obtained by sterile surgical 
excision of a 1 cm-wide circumferential specimen immediately after the 
liver explant in the case of cirrhotic patients, before immersion in the 
preserving UW (University of Wisconsin) cold solution, and after infusion of 
cold preserving UW solution in non-cirrhotic subjects, as part of the 
protocol in explant surgery. Specimens were received on sterile gauze.  
 
 
Sample retrieval and conservation 
 
Samples thus obtained were immediately prepared for conservation using 
a sterile technique. According to the position of the lumen, all samples 
were neatly and sharply sectioned transversally (perpendicularly to the 
luminal surface) into approximately 0.4 cm-diameter fragments for future 
analyses, obtaining fragments of the full-depth vessel wall.  One fragment 
of each venous sample (vena cava and vena porta) was immediately 
conserved in buffered formalin, for immunohistochemical analysis. One 
fragment of each venous sample (vena cava and vena porta) was 
immediately embedded in optimal cutting temperature compound (OCT) 
frozen by isopentane, which was previously cooled using liquid nitrogen. 
The OCT-embedded samples were then placed into criovials and stored in 
liquid nitrogen until surgery was terminated and the team returned to the 
base hospital.  Subsequently, frozen samples were immediately stored at -
80°C and formalin-fixed samples were stored at room temperature until 
processing and analysis.  All samples were processed within six months of 
procurement.  
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Immunohistochemical evaluation of FVIII 
 
Formalin-fixed samples were processed for routine paraffin embedding. 
Serial 2 µm-thick slices were cut using a microtome, mounted onto clean 
slides and stored at room temperature. Thus obtained slices were then 
dewaxed in xylene (twice for 5 min each) and rehydrated through serial 
acohols (100%, 95%, 70%; two changes of 3 min each) to distilled water 
(twice for 5 min each), and air-dried for thirty minutes.  
 
Immunohistochemical staining for factor VIII-related antigen (FVIII-RAG), 
as a marker for endothelial cells (119) was performed with rabbit anti-
human Factor VIII conjugated with horseradish peroxidase antibody (Dako 
Cytomation, Denmark) diluted 1:100 in buffer containing 20 mM Tris-HCL 
pH 7.4 and 150 mM NaCl for two hours at room temperature. The 
antibodies were developed with 3, 3’-diaminobenzidine (DAB, Fluka, 
Milan, Italy), slides were then rinsed in phosphate buffered saline (PBS),  
and slides were mounted using coverslips with Vector ® mounting 
medium.  Examination of the samples was performed with a light 
microscope Leica DMS 5000 (Leica, BM Medical, Padua, Italy).  For this 
analysis all images were viewed and captured at 20 x and 40x 
magnification.  
 
 
Immonofluorescence evaluation of TM 
 
Cryostat sections were prepared from OCT-embedded frozen samples by 
cutting 4 µm-slices at -15° from frozen tissue bound to a chuck, and 
mounted on clean slides using static force. Mounted tissues were stored at 
-20°.   
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Before use, slides were air-dried for 30 minutes.  For immunofluorescence 
analysis, tissue samples were fixed in 2% paraformaldehyde (PF) in PBS 
for 20 minutes at room temperature, treated with 50 mM NH4Cl, and 
permeabilized with 0.5% Triton X-100 in PBS for 15 minutes.  Tissues 
were then incubated for one hour with mouse anti-human TM (Diagnostica 
Stago, Asnières, France) at a concentration of 1:50, as the primary 
antibody. Following two rinsing procedures with PBS, tissues were 
subsequently incubated for one hour with goat anti-mouse IgG Fluorescein 
isothiocyanate (FITC)-conjugated antibody (Diagnostica Stago, Asnières, 
France) at a concentration of 1:400, as the secondary antibody. 
 
Examination of samples was performed with a fluorescent microscope 
Leica IMDM 6000 (Leica, BM Medical, Padua, Italy). FITC fluorescence 
was visualized by excitation at 475-490 and emission at 530 nm.  Cell 
nuclei staining  was performed with Höechst 1 µg/mL for 8 minutes at 
room temperature in the dark and fluorescence of nuclei was visualized by 
excitation at 330-385 nm with a 450 nm barrier filter.  All samples were 
analyzed by differential interference contrast (DIC) objective.  For this 
analysis, all images were viewed and captured at 20x and 40x 
magnification.   
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Results  
 
 
I: Endothelial dysfunction in cirrhosis: characterization of 
structural and functional aspects of the portal vein which 
lead to in situ thrombosis 
 
Four portal vein and four vena cava samples from adult patients with 
cirrhosis were obtained at liver transplantation, and four portal vein and 
four vena cava samples from non-cirrhosis adult controls were obtained at 
surgery for organ donation.  
 
Characteristics of patients and controls 
 
Mean age was 50.25±15.1 in cirrhotic patients, vs 64.75±14.6 in non-
cirrhotic subjects. The etiology of liver disease was HCV in two patients, 
while one patient had autoimmune hepatitis/primary sclerosing cholangitis 
overlap syndrome, and the remaining patient had alcohol-related liver 
disease.  MELD scores were 17, 38, 15, and 20 at liver transplant, and all 
four patients had evidence of portal hypertension, including refractory 
ascites in two, moderate ascites in the other two patients, and esophageal 
varices in three patients. Causes of death in organ donors were: cerebral 
anoxia in two, intracerebral hemorrhage in one, and non-abdominal 
trauma in the remaining patient.  (Table 6).   
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Table 6. Characteristics of patients and controls. Samples of portal 
vein and vena cava were analyzed for each patient. 
 
 
Patients 
(n=4) 
Controls 
(n=4) 
P 
Age (years) 50.25±15.1 64.75±14.6 0.47 
Etiology of liver disease 
HCV n=2, Alcohol-related 
n=1, Overlap syndrome n=1 
-  
Cause of death - 
Cerebral anoxia n=2, 
Intracerebral hemorrhage 
n=1, Trauma n=1 
 
Platelet count (x10
9
/L) 104500±76483 168500±44762 0.2 
INR 1.115±0.02 1.165±0.48 0.9 
PT 67±5.3 78±4.9 0.45 
PTT 28±2.8 27.25±5.67 0.85 
Creatinine (mg/dL) 1.805±0.6 1.34±0.95 0.74 
Hemoglobin (g/dL) 9.15±1.01 11.625±1.9 0.83 
WBC (x10
9
/L 4335±1723 12699.25±3704 0.87 
WBC: white blood cells. 
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Immunohistochemistry 
 
Sixteen samples (portal vein samples and vena cava samples from four 
cirrhosis patients and from four controls) were analyzed. FVIII was 
ubiquitously, consistently, and homogeneously present in all vessels 
studied, delineating the one-cell thick endothelial lining of the portal vein 
and vena cava samples in all patients, without any significant differences 
between patients and controls, nor between vena cava and the portal vein. 
(Figure 5).   
Figure 5. Immunohistochemical peroxidase staining for FVIII of portal 
vein and vena cava of a patient with cirrhosis and a non-cirrhotic 
control.  A) Section of vena cava from control subject. B) Section of vena 
cava from cirrhotic patient. C) Section of portal vein from control subject.  
D) Section of portal vein from cirrhotic patient. *Vessel lumen. **Vessel 
wall, composed of collagen fibers and smooth muscle.  Arrow: Endothelial 
lining.  Objective 20x and 40x. 
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Immunofluorescence 
 
TM was present in the endothelial lining of the portal vein in non-cirrhotic 
subjects.  In contrast, the TM fluorescence signal was less intense in the 
analyzed portal vein sample of a cirrhotic patient. These results are 
preliminary, and represent the portal vein of three control cases and three 
cases of cirrhotic patients. (Figure 6).   
 
Figure 6. Immunofluorescence staining with FITC thrombomodulin 
(TM) on sections of portal vein from a control subject (left panel) and 
from a cirrhotic patient (right panel). 
A;C) interference contrast.  B;D) FITC staining of TM. *Vessel lumen. 
**Vessel wall. Arrow: Endothelial lining which stains for TM). 
Objective 40x magnification. 
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Materials and Methods 
 
Patients  
 
A retrospective analysis of cirrhotic patients prospectively and 
consecutively evaluated and treated for thrombosis of the portal vein 
according to the local anticoagulation protocol at the Multivisceral 
Transplant Unit, Department of Surgical, Oncological, and 
Gastroenterological Sciences of the Padua University Hospital from 
January 2007 to October 2012 was performed. Exclusion criteria were: 
absence of underlying liver disease, present or recent (during the two 
weeks prior to evaluation) use of anti-platelet agents, and the presence of 
hepatocellular carcinoma.  Patients with isolated thrombosis of the 
superior mesenteric vein or splenic vein, without involvement of the portal 
vein, were not included in the analysis.  Upon initial evaluation, and as part 
of the local treatment protocol, every patient underwent clinical evaluation 
and blood sampling.   
 
 
Definition of extent and age of thrombosis 
 
At the first evaluation, all patients underwent computer tomography (CT) 
scanning or magnetic resonance imaging (MRI) to define the grade of 
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occlusion of the vessel(s) and determine the extension of thrombosis into 
the splenic vein and/or the superior mesenteric vein. Thrombosis was 
defined as partial or total, when thrombotic material occupied <90%, or 
≥90% of the vessel lumen, respectively. Thrombus age was estimated 
based on past medical history, analysis of previous radiological studies, 
and radiological characteristics of the thrombus at diagnosis. Thrombus 
was arbitrarily defined as new if there was a recent episode of abdominal 
pain associated with radiological image of PVT compatible with fresh 
thrombus, with no evidence of collateral circulation at hepatic hilum on 
cross-sectional imaging. The thrombus was defined as recent (≤ 6 months) 
when imaging in the previous 6 months demonstrated no thrombosis and 
there was no established cavernous transformation of the portal vein.  
When signs of long standing thrombus were present (i.e. established 
cavernous transformation, defined as multiple small collaterals in and 
around the recanalizing or occluded main portal vein), the time interval 
was determined using previous radiological imaging demonstrating 
absence of thrombosis, and clinical history of previous diagnosis of PVT. 
Based on the thus obtained information, thrombus age was recorded as a 
discrete variable and also classified as ≤6 months or >6 months.  
 
 
Thrombophilia screening  
 
Upon initial evaluation (and before the start of anticoagulation), all patients 
underwent blood sampling for determination of: platelet count, PT, PTT, 
INR,  Lupus Anticoagulant, anticardiolipin and anti-b2 glycoprotein I 
antibodies, levels of antithrombin, Protein C and S antigen and activity, 
activated protein C resistance, Factor VIII, Factor IX, Factor XI, 
Fibrinogen, and FVIII:PC Ratio.  DNA analysis for Factor V Leiden (FVL) 
and Prothrombin G20210A mutations was also performed.   
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Prothrombin time (PT), INR and activated partial thromboplastin time 
(aPTT) were assessed with commercially available methods. Factor II, V, 
VII, VIII, IX, XI activities and fibrinogen levels were measured using 
commercially available reagents on BCT (Siemens, Germany) (120). AT 
activity was detected by a chromogenic method (Antithrombin III, Roche 
Diagnostic, Milan, Italy). Protein C anticoagulant and chromogenic 
activities were assessed using the Protein C and the Berichrom PC kits, 
respectively (Siemens, Germany) on BCT (Siemens, Germany), as 
previously reported (121). Protein S activity was measured using a 
coagulometric method (ProS IL, Milan, Italy) on ACL 9000 (IL, Milan, Italy) 
(122). Activated protein C resistance was measured using a “home-made” 
method on ACL 3000 (IL, Italy) as previously described (123). DNA 
analysis for Factor V Leiden (FVL) and Prothrombin G20210A mutations 
was performed as previously described (124).  Lupus anticoagulant (LAC) 
was detected by PTT-LA (Diagnostica Stago, Asnieres, France) and 
DRVVT (Siemens, Marburg, Germany) on BCT (Siemens, Germany).  The 
presence of LAC was established according to the guidelines of the 
“Scientific and Standardization Committee of the International Society on 
Thrombosis and Haemostasis: Subcommittee of the Lupus An 
ticoagulant/Phospholipid Dependent Antibodies” (125). Anticardiolipin and 
anti-β2-glicoprotein-I antibodies both IgG and IgM were detected by 
commercially available ELISA kits (Orgentec, Mainz, Germany). 
 
 
Anticoagulation protocol 
 
According to the local protocol, before starting anticoagulation, all patients 
underwent full blood count, routine laboratory tests to evaluate coagulation 
and renal function, and endoscopic screening for esophageal varices. 
Patients with previous variceal bleeding and those with Grade II 
esophageal varices with red signs and grade III varices with or without red 
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signs completed variceal eradication by endoscopic band ligation at least 
15 days prior to being started on anticoagulation. The study was 
conducted according to Declaration of Helsinki and patients enrolled in the 
treatment group gave their consent before starting the protocol. 
 
The anticoagulation protocol consisted of administration of LMWH 1.5 
mg/kg/day, and a 40% dose reduction was applied to patients with platelet 
count <50x109/L.  If serum creatinine was >150 umol/L or Creatinine 
Clearance <50 mL/min monitoring of anticoagulation was performed by   
assaying dosage of anti-Xa activity at 6 h after low weight molecular 
heparin (LWMH)  administration. Anticoagulation was continued until 
recanalization or for a period of 12 months.  In cases in which 
recanalization was not achieved after a year of therapy, anticoagulation 
was maintained at a prophylactic dose in order to avoid thrombus 
extension.  
 
 
Follow-up and imaging 
 
All patients were evaluated with abdominal Doppler ultrasound every two 
months during the first six months of therapy, and with CT scan/MRI and 
abdominal ultrasound every six months. Patency of the portal vein was 
assessed at 6 and 12 months from the start of anticoagulation therapy. 
Efficacy of anticoagulation therapy was defined as complete or >50% 
recanalization of the portal vein and its main branches. 
 
 
Analyzed variables 
 
The following patient variables were analyzed: age, sex, etiology of liver 
disease, severity of liver disease according to Child-Pugh class and MELD 
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score, INR, aPTT, PT, platelet count, patient status at timepoints 6 and 12 
months (dead, alive, or transplanted), months of follow-up, plasmatic 
levels of FVIII, FIX, FXI, fibrinogen, antithrombin, protein S, protein C, 
calculus of FVIII:Protein C ratio, and the presence of FV Leiden mutation 
or Prothrombin G20210A polymorphism.  The following variables 
associated to the thrombosis of the portal vein and the anticoagulation 
therapy were analyzed: grade of occlusion of the portal vein, extension to 
superior mesenteric vein and/or splenic vein and/or to intrahepatic 
branches, presence of portal cavernoma, estimated thrombus age at time 
of diagnosis, time interval between thrombus onset and start of 
anticoagulation therapy, achievement of recanalization or failure to 
recanalize, time interval between start of anticoagulation therapy and 
recanalization of the portal vein, progression or extension of thrombosis 
into splanchnic vessels, continuation of anticoagulation at a prophylaxis 
dose or lack of prophylactic anticoagulation after recanalization, the event 
of liver transplant, patency of portal vein at liver transplant, adverse events 
such as bleeding from esophageal varices or other sites, heparin-induced 
thrombocytopenia (HIT), and the need to discontinue anticoagulation 
therapy.  
 
 
Endpoints 
 
The endpoints were (i) complete or > 50% patency of previously 
thrombosed portal vein trunk or main branches; (ii) maintained patency of 
superior mesenteric vein and splenic veins; (iii) progression of thrombosis 
into the portal vein or extension into splenic or mesenteric veins; (iv) 
bleeding, intestinal infarction, liver transplantation or death. 
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Statistical analysis  
 
Quantitative variables are expressed as the mean ± SD and qualitative 
variables as absolute and relative frequencies. Comparisons between 
groups of quantitative and qualitative variables were made by the 
Wilcoxon and Chi square tests respectively. Multivariate analysis of 
variables associated with recanalization was performed by discriminant 
analysis. Time to recanalization rates were assessed using Cox models. 
Comparisons of recanalization rates with risk factors were made by the log 
rank test. All tests were two-sided, and P <0.05 was considered 
significant. Data handling and analysis were performed with SPSS version 
12.0 software (SPSS Inc., Chicago, IL, USA). 
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Results 
 
II. Predictors of response to anticoagulant therapy in 
cirrhosis patients with portal vein thrombosis 
 
 
Medical records for all patients treated with anticoagulation for PVT and 
who were evaluated at the Portal Hypertension Clinic of the Multivisceral 
Transplant Unit of the Padua University Hospital from January 2007 to 
October 2012 were reviewed. Forty-six patients were included in the 
study, and were followed for a mean of 25.2 months (range 3-68 months) 
from the time of initial evaluation for PVT at our center and until the 
closure of the study (October 2012).   
 
 
Patient and thrombus characteristics  
 
The characteristics of the study population and of the thrombosed vessels 
are shown in table 7.  Mean age was 59 years (range 41-80), patients 
were predominantly of male sex (34/46), and mean MELD score was 12.8 
(±4.2).  Estimated thrombus age at diagnosis was ≤6 months in 39/46 
(84.8%) of cases.  Regarding the grade of portal vein occlusion, PVT was 
partial in 36/46 (78%) of cases.  Twenty-one patients (45.7%) had portal 
cavernoma, and PVT was extended into the superior mesenteric vein or 
splenic vein in 14/46 patients, and to the intrahepatic branches in 11 
patients.    
 
Thrombophilic mutations were found in 4 patients (heterozygosity for FV 
Leiden n=2, heterozygosity  for Prothrombin G20210A n=1, and  the 
presence of both mutations in heterozygosity in one single patient).   
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Recanalization under anticoagulation protocol 
 
Fifteen patients underwent banding of esophageal varices before starting 
anticoagulation (mean number of sessions to eradication was 2 (range: 1–
3)). Thirty of the 46 treated patients (65.2%) responded to anticoagulation 
after a mean of 4.5 months (±3.1 months) of anticoagulation (Figure 7); 26 
during the first 6 months of therapy and 4 in the following 6 months of 
therapy. Only 2/11 patients in whom the interval between thrombus onset 
and start of anticoagulation therapy was greater than 6 months presented 
recanalization.  Complete recanalization was achieved in a total of 24 
patients, while in 6 patients recanalization was partial. (Figure 8). 
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Table 7. Characteristics of cirrhotic patients with portal vein 
thrombosis (PVT) treated with anticoagulation and PVT 
characteristics. 
Studied variable P 
Mean age ± SD 59 (41-80) 
Sex (Male/Female) 34/12 
Etiology of liver disease  Alcohol 15/46 
HBV/HCV 22/46 
Cholestatic/ 
Cryptogenic 9/46 
Child-Pugh Class A/B/C 21/19/6 
Thrombus age at diagnosis (mean ± SD) 3.46 ± 3.58 months 
Thrombus age at diagnosis  
≤6 months  
>6 months 
39 
7 
Interval between thrombus onset and start of anticoagulation  4.76 ± 3.89 months  
Interval between thrombus onset and start of anticoagulation   
≤6 months 
>6 months 
35 
11 
Extension to splanchnic vessels  
Superior Mesenteric Vein  
Splenic Vein  
 
11 (23.9%) 
4 (8.7%) 
Extension to intrahepatic branches (yes/no) 11 (23.9%) 
Occlusion grade (total/partial) 10/36 
Presence of cavernoma 21 (45.6%)  
Full-dose therapy  24 (52.2%) 
Reduced-dose therapy  22 (47.8%) 
PT 67.7  ± 15.8 
INR 1.3 ±0.19 
aPTT 36.02 ±7.67 
Factor VIII 164.6±57.9 
Factor IX 82.3±28.1 
Factor XI 66.5±31.1 
Fibrinogen 249.2±146.4 
Antithrombin 65.5±22.8 
Protein S 80 ± 21.1 
Protein C 48.3 ± 19.5 
FVIII:PC Ratio 3.65 ± 1.46 
Platelet count (x109/L) 68.2 ± 30.8 
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Figure 7.   Frequency of recanalization of portal vein at different 
months after the start of anticoagulation treatment.  
Mean = 4.5 months; standard deviation = 3.1; N = 30. 
 
 
 
Adverse effects of anticoagulation therapy were observed in 8 patients: 
bleeding from esophageal varices n = 2, hematuria n = 1, epistaxis n = 1 
(did not require suspension of anticoagulant therapy); cerebral 
hemorrhage n = 1 and HIT (heparin-induced thrombocytopenia) n = 3, in 
all of whom anticoagulation therapy with heparin was suspended. 
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Figure 8.  Therapeutic efficacy of anticoagulation for the treatment of 
portal vein thrombosis in cirrhosis patients after 6 and 12 months of 
anticoagulation therapy. 
 
 
Factors associated with response to anticoagulation 
 
Table 8 summarizes the patient and thrombus characteristics in the group 
of patients in whom recanalization was achieved compared to the group of 
patients in whom anticoagulation therapy did not result in recanalization of 
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the portal vein, and analyzed variables are compared between the two 
groups. 
 
Thrombus age at diagnosis (1.9 ± 1.2 months vs 6.3 ± 4.5 months in the 
recanalization group and in the non-recanalization group, respectively, 
p<.001), the interval between thrombus onset and start of anticoagulation 
(3.2 ± 1.7 months vs 7.78 ± 4.5 months in the recanalization group and in 
the non-recanalization group, respectively, p<.002), and the presence of 
intrahepatic branch extension of the thrombosis (p=.025) were the only 
variables that correlated with response to anticoagulation therapy.  
 
At logistic regression analysis, the interval between thrombus onset and 
start of anticoagulation therapy (≤6 months vs > 6 months in responders 
vs non- responders) correlated with the probability of recanalization 
(p=.0051). A longer interval between thrombus onset and start of 
anticoagulation therapy was associated with therapeutic failure (HR 0.734 
(risk describes the probability of recanalization)).  
 
At  survival  analysis  using  Kaplan  Meier  curves,  the recanalization 
portal  vein showed no significant impact on transplant-free survival. 
(Figure 9) However, mortality was higher in patients who did not present 
recanalization (p=.03); of five deaths in all the study population, four were 
related to PVT: one patient had thrombosis recurrence after recanalization 
had been achieved, but no prophylactic anticoagulation had ensued; one 
death occurred in a patient who never achieved recanalization due to non-
compliance to therapy, and two other deaths occurred in patients in whom 
no recanalization had been achieved, while one death occurred in a 
patient who had adequately responded to therapy, but died on the waiting 
list for LT of hepatic insufficiency.  
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Table 8. Clinical characteristics of patients and portal vein 
thrombosis in patients in whom recanalization was achieved and in 
patients in whom recanalization was not achieved with 
anticoagulation. 
 
Studied variable 
Recanalized  PVT  
n = 30 
Not-Recanalized PVT 
n = 16 
P 
Mean age ± SD 59.5 ± 11.2 58.1 ± 9.8 NS 
Sex (Male/Female) 22/8 12/4 NS 
Etiology of liver disease  Alcohol 11/30 
HBV/HCV 15/30 
Cholestatic/ 
Cryptogenic 4/30 
Alcohol 4/16 
HBV/HCV 7/16 
Cholestatic/ 
Cryptogenic 5/16 
NS 
Child-Pugh Class A/B/C 15/14/1 6/5/5 NS 
Thrombus age at diagnosis (mean ± SD) 1.9 ± 1.2 months 6.3 ± 4.5 months .001 
Thrombus age at diagnosis  
≤6 months  
>6 months 
30 
0 
10 
6 
.001 
Interval between thrombus onset and start of 
anticoagulation  
3.2 ± 1.7 months 7.78 ± 4.5 months .002 
Interval between thrombus onset and start of 
anticoagulation   
≤6 months 
>6 months 
28 
2 
7 
9 
.001 
Extension to splanchnic vessels  
Superior Mesenteric Vein (yes/no) 
Splenic Vein (yes/no) 
9/21  
4/26 
2/14 
0/16 
NS 
Extension to intrahepatic branches (yes/no) 4/26 7/9 .025 
Occlusion grade (total/partial) 6/24 4/12 NS 
Presence of cavernoma 12 9 NS 
Full-dose therapy  13 11 NS 
Reduced-dose therapy  17 5 NS 
PT 69.2 ± 14.2 66.7±18.4 NS 
INR 1.3 ± 0.1 1.4±0.2 NS 
aPTT 35.6 ± 7.6 36.3±7.5 NS 
Factor VIII 158.4 ± 39.0 177.2 ± 90.4 NS 
Factor IX 83.5 ± 25.9 82.5 ± 35.2 NS 
Factor XI 67.4 ± 26.0 68 ± 41.9 NS 
Fibrinogen 233.1 ± 89.0 263.1 ± 227.9 NS 
Antithrombin 63.9 ± 18.8 69.8 ± 30.2 NS 
Protein S 79.7 ± 19.3 84.2 ± 23.7 NS 
Protein C 51.7 ± 16.5 44.2 ± 24.3 NS 
FVIII:PC Ratio 3.3 ± 1.2 4.2 ± 1.7 NS 
Platelet count (x109/L) 84.5 ± 38.2 58.1 ± 23.4 NS 
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Figure 9. Transplant-free survival in cirrhosis patients stratified 
according to response to anticoagulation therapy for the treatment of 
portal vein thrombosis (PVT). 
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Materials and Methods 
 
 
Patients 
 
Thirty patients admitted to the Multivisceral Transplant Unit, Department of 
Surgical, Oncological and Gastroenterological Sciences of the Padua 
University Hospital, who had been previously diagnosed with cirrhosis 
were included in the study, and were prospectively and consecutively 
enrolled for each class of Child Pugh until equal distribution of severity of 
liver disease was attained. Exclusion criteria were: use of antiplatelet 
agents, previous or ongoing anticoagulation treatment, presence of PVT 
and active hepatocellular carcinoma or extrahepatic neoplasm. Two 
cohorts of patients, ten with heterozygous inherited type 1 AT defect and 
ten healthy subjects were used as control groups. Patients with type 1 AT 
deficiency presented approximately 50% reduction of both AT antigen and 
activity and belonged to thrombophilic families that have been previously 
studied (126;127). None of the patients with inherited AT deficit  presented  
other associated thrombophilic defects. Exclusion criteria for the control 
groups were: age younger than 18 years, pregnancy, presence of active 
cancer, ongoing anticoagulant or hormonal treatments, and history of 
previous thrombotic events. Informed consent according to the Helsinki 
Declaration was obtained from each patient before inclusion in the study. 
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Blood collection and plasma preparation 
 
Fasting whole blood samples (15 mL) from each patient and control were 
drawn by clean venipuncture and collected into vacuum tubes containing 
109 mmol/L trisodium citrate as an anticoagulant, at a blood to 
anticoagulant ratio of 9:1, using the BD-Vacutainer® system (Plymouth, 
UK).  Platelet poor plasma was prepared by double centrifugation at 2000 
g for 10 min. Plasma was aliquoted in plastic tubes, snap-frozen and 
stored at -80 °C until use. 
 
 
Thrombophilia screening and evaluation of coagulation factors 
 
Prothrombin time (PT), INR and activated partial thromboplastin time 
(aPTT) were assessed with commercially available methods. Factor II, V, 
VII, VIII, IX, XI activities and fibrinogen levels were measured using 
commercially available reagents on BCT (Siemens, Germany) (120). AT 
activity was detected by a chromogenic method (Antithrombin III, Roche 
Diagnostic, Milan, Italy). Protein C anticoagulant and chromogenic 
activities were assessed using the Protein C and the Berichrom PC kits, 
respectively (Siemens, Germany) on BCT (Siemens, Germany), as 
previously reported (121).Protein S activity was measured using a 
coagulometric method (ProS IL, Milan, Italy) on ACL 9000 (IL, Milan, Italy) 
(122). Plasminogen activity was evaluated by a chromogenic method 
(Berichrom Plasminogen, Siemens, Germany). Activated protein C 
resistance was measured using a “home-made” method on ACL 3000 (IL, 
Italy) as previously described(123). DNA analysis for Factor V Leiden 
(FVL) and Prothrombin G20210A mutations was performed as previously 
described  (124).    Lupus anticoagulant (LAC) was detected by PTT-LA 
(Diagnostica Stago, Asnieres, France) and DRVVT (Siemens, Marburg, 
Germany) on BCT (Siemens, Germany).  The presence of LAC was 
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established according to the guidelines of the “Scientific and 
Standardization Committee of the International Society on Thrombosis and 
Haemostasis: Subcommittee of the Lupus An ticoagulant/Phospholipid 
Dependent Antibodies” (125) Anticardiolipin and anti-β2-glicoprotein-I 
antibodies both IgG and IgM were detected by commercially available 
ELISA kits (Orgentec, Mainz, Germany). 
 
 
Addition of Enoxaparin to plasma samples 
 
Enoxaparin (Clexane® (Sanofi-Aventis) at 0.5 UI/mL or 0.7 UI/mL final 
anti-Xa concentration was added to plasma samples of every cirrhotic 
patient, patients with genetic AT deficit, and controls.   
 
 
Anti-Xa activity measurement 
 
Anti Xa activity was measured at basal conditions and after addition of 
enoxaparin at a final concentration of 0.35UI/mL and 0.7 UI/mL of anti-Xa 
activity through an amidolytic method according to the manufacturer 
instructions, with the BCT (Siemens, Germany). A fixed concentration of 
bovine activated factor X (FXa) and a chromogenic substrate are added to 
the plasma sample. Hydrolyzation of the substrate mediated by FXa 
depends on the inhibition of FXa acted by the complex heparin-
antithrombin  present in the tested plasma sample. The hydrolysis of the 
substrate is inversely proportional to the LMWH concentration present in 
the plasma sample. 
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Thrombin Generation 
 
Thrombin generation test (TGT) was performed on platelet-poor plasma 
(PPP) with the fluorimetric method described by Hemker, Calibrated 
Automated Thrombogram® (CAT)(44;45) and expressed as Endogenous 
thrombin potential (ETP). In this test, coagulation is activated on PPP, 
using  the commercial  trigger composed of recombinant tissue factor (TF) 
at a concentration of 5 pM and phospholipids at a concentration of 4μMol. 
Thrombin generation curves were calibrated with a thrombin Calibrator 
(Thrombinoscope BV, Maastricht, The Netherlands) at each cycle of the 
test.  
 
A fluorogenic substrate (Z-Gly-Gly-Arg-AMC, BACHEM AG, Bubendorf, 
Switzerland) was dispensed in each well at a final concentration of 300 μM 
to allow a continuous registration of thrombin generation, fluorescence 
produced was read in real time by a fluorometer, Fluoroskan Ascent® 
(Thermo Labsystems, Helsinki, Finland). A software (Thrombinoscope BV, 
Maastricht, The Netherlands)® recorded fluorescence generated and 
created a curve of thrombin generation. The area under the curve is 
expressed as ETP, while the peak of the curve corresponds to the peak of 
thrombin generated (CMax.) 
 
TG with determination of ETP was performed at basal conditions and after 
addition of enoxaparin at a final concentration of 0.35UI/mL and 0.7 UI/mL 
of anti-Xa activity. The anticoagulant effect of enoxaparin was expressed 
as the ratio between ETP after addition of anticoagulant (0.35 ETP ratio 
and 0.7 ETP ratio) and ETP obtained at basal conditions in each group of 
patients and controls. 
 
TG tests were performed in the same way in another aliquot of plasma 
with the addition of soluble (TM) (Recombinant human thrombomodulin 
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(CD141), American diagnostica inc., Stamford, USA), at a final well 
concentration of 6nM. 
 
Statistical Analysis 
 
Continuous variables were expressed as mean ± standard deviation (SD) 
or as medians and ranges. The nonparametric Mann-Whitney U and 
Kruskal-Wallis H  test were used to test for differences between median 
values when appropriate. Spearman’s correlation coefficient was used to 
assess correlation between continuous different variables and Pearson 
Chi-square or Fisher’s exact test with Pearson Correlation Coefficient for 
dicothomus variables. P values of .05 or less were considered statistically 
significant. All analyses were performed with SPSS version 11.5 software 
(Chicago, IL). 
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Results 
 
III. Anticoagulant response to low-molecular-weight heparin 
in plasma from patients with advanced cirrhosis.  
 
 
Patient characteristics and coagulation profile 
 
The main characteristics of the study population are reported in Table 9. 
Thirty patients with cirrhosis, (24 males and 6 females), were included, 
and they were equally distributed according to the severity of liver disease 
as expressed by the  Child Pugh classes (10 Child Pugh A, 10 Child Pugh 
B, and 10 Child Pugh C patients). Ten patients with heterozygous type 1 
AT defect and 10 healthy subjects were included as controls. 
 
 
Table 9. Demographic and clinical characteristics of cirrhosis 
patients, subjects with genetic antithrombin defect, and healthy 
controls. 
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Plasma activity of coagulation factors and inhibitors, platelet count, aPTT, 
INR and PT are shown in Table 10. Patients with AT deficiency had lower 
levels of AT, and patients with liver cirrhosis showed a statistically 
significant prolongation of aPTT and INR, a decrease in PT and all 
measured coagulation proteins, except for factor VIII, as compared to 
controls. The reduction in levels of plasmatic factors was consistent  with 
the severity of liver disease.  In particular , patients with Child Pugh C 
cirrhosis were characterized by lower AT activity levels than patients with 
AT inherited defect (42±14% versus 52±4%, respectively,  p=.06) (Figure 
10) 
 
No patient or control had antiphospholipid antibodies and none was carrier 
of factor V Leiden and/or prothrombin G201210A mutation. 
 
 
 
Table 10. Coagulation parameters in controls, cirrhotic patients, and 
patients with antithrombin defect type 1. 
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Figure 10. Plasmatic coagulometric antithrombin activity in healthy 
controls, cirrhotic patients distributed according to Child Pugh class, 
and in subjects with genetic antithrombin defect type 1. 
 
 
Determination of anti-Xa activity in plasma 
 
After the addition of  LMWH to plasma samples at an estimated final 
concentration of LMWH 0.35 UI/mL, measured values of anti-Xa activity 
were 0.36 ± 0.04 UI/mL in healthy subjects, 0.34 ± 0.05 UI/mL, 0.27 ± 0.6 
UI/mL, 0.21 ± 0.09 UI/mL in Child Pugh A, Child Pugh B, and Child Pugh C 
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class cirrhotic patients, respectively, and 0.34 ± 0.01 UI/mL in patients with 
congenital AT defect. At LMWH 0.35 UI/mL concentration, anti-Xa activity 
was significantly lower in Child Pugh B and Child Pugh C patients as 
compared to controls (p<0.001), as well as in patients with congenital AT 
defect as compared to controls (p<0.001). Likewise, at LMWH 0.7 UI/mL, 
anti-Xa activity was significantly lower in Child Pugh B and Child Pugh C 
cirrhotics (0.59±0.03 and 0.51±0.08 UI/mL) and in patients with AT defect 
(0.64 ± 0.04 UI/mL) than in controls (0.72 ± 0.009 UI/mL) (p<0.001), and in 
Child Pugh C cirrhotics than in patients with AT defect (p<0.001).  
 
 
 
Thrombin generation 
 
When thrombin generation was performed without addition of enoxaparin, 
patients with cirrhosis showed decreased endogenous thrombin potential, 
expressed as ETP (nMol*min), as compared to controls and to patients 
with congenital AT defect, independently of the severity of liver disease 
(Figure 11).  
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Figure 11. Native endogenous thrombin potential (ETP) in healthy 
controls, cirrhotic patients according to Child class, and subjects 
with genetic antithrombin defect type 1. 
 
 
After the addition of enoxaparin at a final concentration of 0.35 IU/mL, 
there was a significantly greater decrease in thrombin generation in 
controls than in patients with congenital AT defect, with a mean ETP 
reduction of 51.6±14% and 30.8±10%, respectively (p=.003).  Despite low 
levels of AT and anti-Xa activity, patients with cirrhosis showed a greater 
anticoagulant effect of LMWH, with a mean ETP reduction of 72.6±11% 
(p=0.02 versus controls). 
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The decrease in thrombin generation with LMWH in cirrhotic patients 
mirrored the severity of liver disease. Although Child Pugh class C patients 
had AT levels similar to patients with heterozygous AT defect, they 
exhibited the greatest reduction in ETP, with a mean reduction of 82.6 ± 
10% . On the contrary, patients with AT defect were characterized by an 
apparent low response to LMWH with a mean reduction of ETP by 
30.8±10% with respect to  basal conditions.  
 
In cirrhotic patients, the anticoagulant response to LMWH at an estimated 
concentration equal to  0.35 IU/mL of anti-Xa activity expressed as ETP 
ratio correlated with all coagulation parameters tested, except for 
INR.(Table 11). 
 
 
Table 11. Correlations between coagulation parameters and ETP ratio 
0.35 in cirrhotic patients. 
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Interestingly, the plasma AT activity level was the parameter that most 
strongly correlated with the response to LWMH expressed as ETP ratio 
(r=.64, p<0.001) (Figure 12).  
 
No correlation was found between ETP ratio 0.35 and severity of liver 
disease expressed as Child Pugh score, or serum bilirubin, albumin or 
creatinine levels.   
 
When thrombin generation was performed after addition of enoxaparin at a 
final concentration of  0.7 UI/ml, ETP was not measurable in 9 (4 in Child 
Pugh B and 5 in Child Pugh C) out of 20 patients with more advanced 
cirrhosis because of complete abolition of thrombin generation, as 
compared to 1 out of 10 controls. In the remaining samples, in which 
generated thrombin reached a measurable threshold, the anticoagulation 
was almost complete in all groups, with ETP ratio 0.7 of 0.26±0.08, 
0.19±0.06, 0.10±0.08 in Child Pugh A, B, and C cirrhotic patients 
respectively), compared to 0.15±0.15 in controls. Patients with 
heterozygous AT defect showed “resistance” to LMWH, with an ETP ratio 
of 0.56±0.47. 
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Figure 12. Correlation between endogenous thrombin potential (ETP) 
ratio at 0.35 UI/mL and plasmatic antithrombin levels. 
 
 
 
In native plasma, amongst patients with cirrhosis, only those in Child Pugh 
class C showed a significant increase in the ETP ratio with and without 
(TM), compared with controls and patients with AT genetic defect 
(0.97±0.03 vs 0.85±0.05, and 0.87±0.06, respectively, P<.05).(Figure 13).   
After the addition of enoxaparin at  a final concentration of 0.35 IU/mL, the 
ETP ratio with and without TM  mirrored the results obtained in the native 
samples (Figure 14). Moreover, when thrombin generation was performed 
after the addition of enoxaparin at  a concentration of  0.7 IU/ml in samples 
with the addition of TM, ETP was not measurable in 7 cirrhotic patients 
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(three Child Pugh B and four Child Pugh C), and again in one of the 
controls, similarly to the results obtained in samples without the addition of 
TM. 
 
 
 
 
Figure 13. Distribution of values of ETP ratio between thrombin 
generation assessed with and without TM for healthy subjects and 
patients with cirrhosis stratified according to classes of Child Pugh. 
ETP=Endogenous Thrombin Potential, TM=Thrombomodulin 
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Figure 14. The ETP ratio of plasma with 0.35 UI mL enoxaparin to 
native plasma in samples with 6 nM TM in healthy controls, cirrhotic 
patients according to Child Pugh classes and subjects with a genetic 
antithrombin (AT) defect type 1. 
ETP=Endogenous Thrombin Potential, TM=Thrombomodulin 
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According to Virchow’s triad, the three key role players in the formation of 
thrombosis are: blood stasis, alterations of the coagulation cascade, and 
endothelial dysfunction.  In cirrhosis patients, the most common site of 
thrombosis is the portal vein, probably reflecting the consequence of all 
three mechanisms.  Venous stasis present in portal hypertension due to 
the architectural derangement of the cirrhotic liver, likely combines with an 
endothelium that has lost, partially or completely, its anticoagulant 
properties.  The characteristic altered coagulation status of advanced liver 
disease, characterized by diminished levels of pro- but also anti-coagulant 
circulating factors, probably also contributes to the establishment of portal 
vein thrombosis.  
 
The arm-to-tongue circulation time of the blood (∼30 seconds) is short 
compared with a whole blood clotting time, so thrombin formed in flowing 
blood in vivo is rapidly diluted and inactivated before clotting can occur. 
Thrombin only builds up in unstirred boundary layers at cell surfaces and 
in the stagnant plasma caught in a clot or an aggregate, and transport by 
diffusion will therefore tend to govern reaction rates (42).   Within the 
portal vein of cirrhosis patients, flow is severely hampered, with inversion 
of flow direction being a relatively common finding (128).  In the study by 
Zocco and collaborators, where portal flow velocity was determined using 
Doppler ultrasound in cirrhotic patients who were subsequently followed 
for the development of PVT, patients who developed PVT had a mean 
basal value of portal flow velocity of 11.8 ± 2.6 cm/s, and a velocity below 
15 cm/s was the only independent predictor of occurrence of PVT(75).  
Notably, however, low flow in the portal vein (19.6 ± 5.7 cm/s) was also 
found in all cirrhotics, also in those who had not developed PVT one year 
after initial Doppler evaluation.  Venous stasis can favor the initiation of the 
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coagulation cascade, which, in the presence of an endothelium that has 
lost its anticoagulant properties, may result in thrombus formation. 
 
Actual development of thrombosis has been demonstrated to injure the 
venous wall, causing a reaction that has been described as similar to 
wound healing, associated with increased procollagen, total collagen, and 
metalloproteinases (129).   
 
Not only existing thrombosis, however, but also hypertension, has been 
experimentally shown to induce measurable changes. Hayashi et al. used 
a rabbit model in which left femoral venous pressure was elevated by 
constriction of the external iliac vein (130). Compared with the 
contralateral normal vein, the femoral vein, which experienced the higher 
intravascular pressure (16 vs 7 mmHg), displayed increased wall thickness 
and elevated vascular tone.   
 
Regarding the integrity of the endothelium’s anticoagulant functions, TM 
plays a fundamental role and was therefore studied.  TM is an integral 
membrane glycoprotein that has a major role in the regulation of 
intravascular coagulation(131).  This glycoprotein can change the function 
of thrombin, the main procoagulant enzyme, to an anticoagulant through 
activation of the protein C pathway(132). In turn, activated protein C in the 
presence of protein S inactivates factor VIIIa and factor Va, and thereby 
inhibits further formation of thrombin.   
 
High levels of circulating TM have been demonstrated after induction of 
liver damage in animal models and other diseases with systemic 
inflammation(93;133).  Circulating TM has been found to be either normal 
or elevated in patients with liver disease, and to be correlated with 
endothelial damage, without showing, however, a direct relationship with 
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the degree of portal hypertension. A correlation with severity of liver 
disease has been described, however (134).  
 
In the study by Remkova and collaborator (135), the Authors explored  
plasmatic levels of homocysteine in relation to soluble TM and von 
Willebrand Factor (vWF) as markers of endothelial dysfunction in 71 
patients with varying severity of chronic liver disease, and compared them 
to those of 51 healthy subjects.  Homocysteine, TM, and vWF were all 
elevated in patients with chronic liver disease, but only the last two 
markers showed a statistically significant correlation with increasing 
severity of liver disease. Circulating levels of TM, determined using ELISA, 
were increased in steatosis (P=0.029), Child A cirrhosis (P=0.0010), and 
Child B and Child C cirrhosis (P<0.0001, respectively), whereas circulating 
levels of vWF, determined using the same methodology, were elevated in 
Child A cirrhosis (P=0.0003) as well as in Child B and C cirrhosis 
(P<0.0001, respectively).   
 
In the present study, immunohistochemical analysis of portal vein samples 
in cirrhotic patients demonstrated low levels of endothelial TM.  Although 
apparently contradictory with respect to the above mentioned study, 
elevated circulating TM levels can be a consequence of endothelial 
damage, where previously bound TM is shed into the bloodstream.  
Although TM is mostly located on endothelial cells of arteries, veins, and 
capillaries, there is a small amount of circulating, soluble TM, and albeit its 
function is unclear,  there is evidence that its presence signifies 
endothelial-cell damage(136;137). A positive association between soluble 
TM and different manifestations of endothelial damage, such as coronary 
heart disease and peripheral occlusive arterial disease, has been 
shown(138).  Furthermore, although dealing with arterial damage rather 
than venous endothelial injury, in a study by Blann and collaborators(139),  
it was reported that among 54 survivors of myocardial infarction, soluble 
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TM was directly related to the risk of a recurrent cardiovascular event 
during 49 months of follow-up.   
 
In cultured human umbilical vein endothelial cells, the group of Kapiotis et 
al (140) demonstrated that TM was downregulated by the pyrogens IL-1, 
TNF, and lipopolysaccharides to less than 50% of TM activity of untreated 
cells. Interestingly, TM downregulation was completely neutralized when 
these mediators were co-incubated with IL-4, of known anti-inflammatory 
properties.  In this same report, it was shown that lipopolysaccharide 
infusion reduced TM messenger RNA to less than 40% that of untreated 
cells, parallel to the decrease in TM surface activity, and this effect was 
partly antagonized by IL-4, which in part protects endothelial cell surface 
against pyrogen-induced procoagulant changes. As evidenced by this 
study, surface TM may be regulated at the transcriptional level.  In the 
rabbit model, Semeraro and collaborators demonstrated decreased levels 
of TM messenger RNA after lipopolysaccharide infusion in rabbits, 
coupled to normal levels of the actual protein (141).  In another study, 
Terada et al demonstrated that endothelial injury induced by 
lipopolysaccharide infusion reduced TM in the endothelia of lung, liver, 
and peritubular capillaries in rats(142).  
The present is the first study that has been performed which analyzes the 
endothelium lining the portal vein of cirrhotic patients, demonstrating that 
TM is reduced at this level, with conservation of FVIII. Diminished levels of 
TM may lead to insufficient activation of Protein C, and therefore 
hampering of Factor V and Factor VIII blockade, the latter of which is 
present within the endothelium of the portal vein, as hereby demonstrated.   
 
Regarding interactions between anticoagulant components, endothelial 
protein C receptor (EPCR), which is ubiquitously expressed on the 
endothelium of all arteries and veins, especially those of large and 
medium caliber like the portal vein and hepatic vein, promotes, together 
79 
 
with TM, protein C activation by increasing at least by 5-fold the catalytic 
efficiency of the thrombin-thrombomodulin complex. Although it has been 
demonstrated that soluble levels of EPCR are increased in chronic liver 
disease (143), this may be not sufficient to compensate for the low levels 
of TM that have been found in the present study.  It is possible, moreover, 
that endothelial damage diminishes not only TM, but also EPCR, further 
compromising the anticoagulant mechanisms of the endothelium.  This 
issue has not yet been explored, and future studies in this direction could 
help clarify the interactions of these proteins with the other anticoagulant 
components within the endothelium of the portal vein and other venous 
territories in cirrhosis patients.  
 
Factor VIII (FVIII), on the other hand, is a pro-coagulant factor which is 
ubiquitously expressed in the endothelium.  It is an essential cofactor for 
FIXa-mediated catalysis of factor X to Xa. In its soluble form, FVIII is 
notably increased in cirrhosis, and the most widely accepted mechanism is 
the increase of von Willebrand factor, to which it binds when in circulation. 
An established marker of endothelial dysfunction, the elevation in FVIII 
has been shown to parallel the increase in severity of liver disease (144-
146).  
 
As demonstrated in the present study, portal vein endothelium in cirrhosis 
patients, as well as systemic venous territories as represented by the vena 
cava, do not show differences with regard to the presence of FVIII, which 
appears consistently conserved.  The coupling between diminished TM 
and conserved FVIII may represent hampering of a protective 
anticoagulant mechanism by the first, and the maintenance of a pro-
coagulant mechanism by the latter, which possibly favor the development 
of PVT.  
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It is possible that the one-cell thick endothelial lining of the portal vein and 
of veins in the systemic circulation is structurally conserved (as 
demonstrated by positivity of FVIII), but that it lacks functional dynamics 
such as that established with the overlying glycocalyx.  Likewise, other 
functional alterations may coexist, such as demonstrated by diminished 
presence of TM.   
 
The analysis of more samples will be useful in confirming these results, 
which represent a preliminary approach, and represent an invaluable step 
in perfecting preservation techniques, opening a vast array of possibilities 
regarding analysis of portal vein endothelium as a specific site for 
thrombosis.   
   
Portal vein thrombosis is a common complication in cirrhosis, with a 
reported prevalence of up to 25% in patients without HCC and 33% in 
those with HCC (74). Despite it being frequently encountered in end stage 
liver disease and therefore in liver transplant candidates, definitive 
guidelines for the treatment of PVT before transplantation are not available 
(147). 
Actual experience in the treatment of thrombotic complications in cirrhosis 
patients is limited.  In a retrospective study analyzing 17 cirrhosis patients 
with VTE, it is reported that 11 patients were treated only with LMWH and 
six patients received LMWH during the first week, followed by Vitamin K 
Antagonists (VKA).  Eighty-three percent of patients (14 of 17) presented 
bleeding complications, six of which were severe and required blood 
transfusions, corresponding to one patient treated with LMWH and five 
patients treated with VKA. For this reason, anticoagulation was withdrawn 
in most patients, and only three remained on anticoagulant therapy for 6 
months(60).  
 
81 
 
Notwithstanding existing evidence in favor of avoiding thrombosis 
progression, current guidelines do not comprise treatment strategies for 
management of patients in the waiting list for liver transplantation. To date, 
135 cirrhotic patients with PVT in 4 published cohorts have been treated 
with anticoagulation, resulting in a portal vein recanalization rate ranging 
from 46% to 85% (70;148-150).  
 
In the prospective study by Francoz et al (70), 19 cirrhosis patients 
evaluated for liver transplantation, 18 with partial and one with complete 
PVT, were treated with LMWH followed by VKA, and were compared 
against a historical control group of 10 patients who received no 
anticoagulation.  All but two anticoagulated patients in Child class B or C, 
and fourteen had had previous variceal bleeding.  The rate of complete 
recanalization was 42.1% at the end of follow up, but few details were 
provided about the time interval between the diagnosis of thrombosis and 
anticoagulation, and the time interval between the start of anticoagulation 
and recanalization.  It is noteworthy that patients with complete PVT at the 
time of liver transplantation had significantly lower survival after transplant. 
This further confirms the fact that at least in patients with cirrhosis and 
PVT listed for liver transplantation, anticoagulation should be used.  
 
In the second study by Amitrano et al. therapeutic dose (200UI/KG/die) of 
LWMH was used in 29 patients with cirrhosis and PVT. Recanalization 
was attained  in 33.3% of cases within 6 months of treatment, but reached 
a 75% rate in those patients  who continued anticoagulation treatment 
beyond 6 months, with time to recanalization which ranged from 1 to 17 
months(148). This percentage is exceptionally high in comparison with the 
efficacy of anticoagulation in a non-cirrhotic population with PVT (27%-
45.4%) and cannot be explained either by the time interval to 
anticoagulation, nor by the presence/absence of underlying thrombophilic 
conditions, which were not investigated by the authors. 
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In the retrospective study by Delgado et al, analyzing data from 55 
cirrhosis patients with PVT who received anticoagulant therapy for acute 
or subacute thrombosis (n=31), or due to progression of previously known 
PVT (n=24), partial or complete recanalization was achieved in 33 
patients, and early initiation of anticoagulation was the only factor which 
was significantly associated with anticoagulant response.  After stopping 
anticoagulation, 5 of the 13 patients who had had recanalization on 
anticoagulant therapy presented rethrombosis of the portal vein a median 
of 1.3 months after cessation of anticoagulation. The Authors of this study 
recommend the lifelong maintenance of anticoagulant therapy after 
thrombus disappearance (151).   
 
Senzolo and collaborators recently published a prospective study 
proposing an algorithm for the treatment of PVT in cirrhosis including the 
use of anticoagulation and transjugular intrahepatic portosystemic, and 
report on several patients which are comprehended in the present study 
population, but also on the group of patients from Royal Free Hospital that 
constituted the untreated arm (152). In that study, 35 patients were 
included in the protocol and 33 were anticoagulated with the standard 
therapeutic dose of nadroparin (95 anti-Xa U/Kg body weight td), with a 
40% dose reduction with platelet count below 50000x109/L. A complete 
recanalization rate of 36% was reported, and partial response to 
anticoagulation therapy was seen in 27% of patients. Mean interval 
between starting of anticoagulation and recanalization was 5.5±2.6 months 
(range 1-10).  
 
The present study, which aside from broadening the study population, 
explores the coagulation profile as a possible predictor of response to 
anticoagulation, largely confirms these results, with a response rate of 
65%. Complete recanalization rates are higher (52%), at the expense of a 
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smaller percent representation of partial recanalization rates (13%). This 
can be explained by the fact that the present study includes recently 
evaluated and treated patients, who presented for evaluation with a recent 
thrombus onset, due to the ever-increasing awareness of the feasibility 
and importance of anticoagulation treatment in these patients, which is 
reflected on increased referral to tertiary centers. The present study also 
confirms that the time interval between diagnosis of PVT and 
anticoagulation is the strongest predictor of response to anticoagulant 
treatment.  
 
These data are similar to those obtained in the non-cirrhotic population 
with PVT reported by Plessier et al (112), in which the one year 
recanalization rate was 38%, with no patient obtaining recanalization   
when anticoagulation was started beyond 12 months from the diagnosis of 
PVT. Interestingly, in this series evaluating non-cirrhotic patients with PVT, 
the presence of ascites and thrombotic splenic vein involvement were 
independently associated with failure to obtain recanalization.   
 
This probably confirms that chronicity of the thrombus (clinically 
associated with the appearance of portal hypertension in non-cirrhotic 
patients) is associated with the lack of efficacy of anticoagulation. In 
contrast with the study by Amitrano and collaborators, anticoagulation was 
continued for another 6 months in the case of those patients who had not 
achieved recanalization after the first 6 months(148).  
 
Importantly, an aspect that could contribute to the lack of response to 
anticoagulation in some patients can be owed to the fact that a worse 
stage of liver disease can preclude a prolonged anticoagulation treatment. 
However, lack of studies do not allow for clarification of this bias; present 
evidence does not indicate that patients followed have had to abandon 
anticoagulant therapy prematurely due to increasing severity of liver 
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disease, or have perished while on anticoagulant therapy, thus reducing 
the available time for thrombus resolution.  Arguably, liver disease is less 
severe in patients who are able to tolerate anticoagulation for several 
months before undergoing liver transplant, and this could represent an 
inherent bias.  However, in the few studies published, patients with severe 
liver disease have been included (Child C cirrhosis), and this has not 
hampered the efficacy of anticoagulation, and comparability of groups 
anticoagulated vs non-anticoagulated have been corroborated, with the 
exception of variceal bleeding being less frequent in groups undergoing 
anticoagulation(70;148). 
 
In the present study, thrombosis progression was observed in one of four 
patients who did not complete 12 months of anticoagulation, within 2 
months of anticoagulation cessation. Of 9 non-responders who completed 
12 months of anticoagulation, two had thrombosis progression after 3 and 
4 months of anticoagulation cessation, respectively, and in the absence of 
prophylaxis. Two other patients presented thrombosis recurrence after 1 
and 4 months of anticoagulation cessation after obtainment of complete 
recanalization, in the absence of prophylaxis.  In contrast, no patient on 
prophylaxis presented thrombus recurrence, 16 after complete or partial 
response to therapy, and 7 after a course of 12 months of anticoagulation 
without obtainment of recanalization.  
 
These data are similar to those reported by Amitrano et al (148), where 
thrombus progression was reported in 2/5 of non-responders, and in 1/10 
of non-responders in the study by Francoz et al(70). In patients who were 
not anticoagulated, thrombus extension was observed in 6/10 patients.  
 
In the present study, albeit 86.7% of patients in whom recanalization was 
achieved this event occurred within the first 6 months of therapy, in 4/30 
patients this event was attained in the subsequent 6 months of 
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anticoagulation, which supports the notion that it is worthwhile to continue 
anticoagulation therapy beyond the initial 6 months, for a similar period of 
time.   
 
The present study underlines the two important steps which must be met 
in the management of this complication in cirrhosis: early diagnosis and 
early treatment. Early start of anticoagulation therapy after thrombus 
formation was the most important predictor of efficacy of anticoagulation 
for the treatment of PVT in cirrhosis patients, and from this derives the 
importance of not delaying diagnosis.  An old, organized thrombus is less 
likely to disappear on anticoagulation therapy with respect to a fresh 
thrombus.  
 
This is in line with what reported by Delgado et al (153), in that the only 
factor that was statistically associated with the therapeutic efficacy of 
anticoagulation was the delay in start of treatment (15±27 days in 
responders vs 55±86 days in non-responders, p=.042). This group also 
confirmed the lack of association between efficacy of anticoagulation 
therapy and studied factors such as age, gender, history of previous 
variceal bleeding, history of encephalopathy, previous episodes of portal 
hypertension decompensation, Child-Pugh score, platelet count (x109/L), 
renal function, presence of an underlying thrombophilia, presence of 
symptoms at diagnosis, extension of PVT into the splachnic vasculature, 
and presence of ascites.  
 
Similarly, the presence of thrombophilia, as well as the coagulation status, 
as described by the determination of coagulation factors does not seem to 
influence response to anticoagulation. In the present study, in fact, 
response to anticoagulation therapy neither thrombus progression nor 
recurrence were associated with coagulation factors nor thrombophilic 
defects. However, it is noteworthy that these tests offer only an 
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approximation of the actual hemostasis-coagulation dynamics taking place 
inside the portal vein. On the other hand, Amitrano and collaborators did 
not find any differences in clinical features or extension of portal 
thrombosis between early or late responders and those that were non-
responders to anticoagulation (148).  
 
In the present series, aside from a long-standing thrombus, the extension 
of thrombosis into intrahepatic branches was another negative predictors 
of response. The latter was associated with increasing severity of liver 
disease, although the correlation did not reach statistical significance, but 
this is probably due at least in part to the small number of patients with this 
particular condition.   
 
Interestingly, response to anticoagulation was independent of the stage of 
cirrhosis and of the use of a full dose or a reduced dose of anticoagulation, 
which is dictated by platelet number and therefore correlates with severity 
of liver disease.  These data support the notion that even patients with 
advanced cirrhosis may benefit from anticoagulation, and that if a full dose 
is not possible, recanalization can still be attempted with dose reduction.   
 
In the present study, neither occlusion grade nor extension to other 
splanchnic vessels were associated with the efficacy of anticoagulation. 
This probably reflects the fact that acute thrombosis can debut as an 
extensive thrombus, and thrombus extension is not necessarily a temporal 
becoming of a chronic thrombosis, and that acutely formed, fresh thrombi 
are more susceptible to the action of anticoagulants.  In the study by 
Francoz and collaborators (70), factors that were associated with 
response to anticoagulation were not specifically sought for; however, the 
only case of complete PVT was found in the group of non-responders. 
However, only one of 19 treated patients had complete occlusion, and 
therefore no conclusions can be drawn from this data.   
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Regarding the importance of opportune treatment, this relies partly on 
diagnosing PVT within the first 6 months of its onset. Doppler ultrasound is 
the first-line method used to diagnose PVT, whereas CT scan and MRI 
have largely substituted angiography as a confirmation method in the last 
decades. In 409 patients with surgically confirmed PVT from thirteen 
studies (73;82;85;86;99;106;154-160), preoperative imaging detected the 
presence of PVT in 53% of the cases.  The reported rate of preoperative 
detection of PVT ranged from 21% (99) to 87%(156;158), and this could 
depend primarily on two factors: the grade of thrombosis and each 
center’s radiological follow-up protocol, which determines the time interval 
between imaging and transplant. Whereas sensitivity for grade III-IV PVT 
ranges from 92% to 100%  (83;88;161;162), sensitivity in partial PVT and 
Grades I-II PVT is much lower (14.3% to 50%)(83;99;161). 
 
The timely diagnosis of PVT is crucial in determining a successful outcome 
of anticoagulant therapy, and therefore, periodic evaluation with abdominal 
Doppler ultrasound is mandatory.  There is no evidence, however, to 
recommend very short imaging intervals, as it has been shown that 
ultrasound and CT scan every 2 months does not improve the rate of 
detection of partial PVT (160;161). The widely used 6-month interval 
seems to represent the optimal compromise. 
 
Bleeding, especially life-threatening hemorrhage such as variceal 
bleeding, is the most feared complication of anticoagulant therapy, 
although it has been demonstrated that hemodynamic factors, such as 
variceal pressure, are the greatest determinants of the likelihood of these 
events, and not the coagulation status(163).   
 
The choice of using LWMH seems safe in patients with advanced liver 
disease. In the study by Francoz et al, only one of the 19 patients treated 
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with anticoagulation presented upper gastrointestinal bleeding, but in this 
case the bleeding episode was caused by a post ligation ulcer, and 
anticoagulation did not have to be discontinued in any patient (70). In the 
study by Amitrano and collaborators, of 28 patients treated with 
anticoagulation, none presented side effects such to consider interruption 
of therapy; mild anemia due to portal hypertensive gastropathy was seen 
in two patients, improving after iron supplementation  (148).  Delgado et al 
report bleeding related to anticoagulation (variceal bleeding in all) in 5  of 
55 treated patients, and platelet count below 50x109/L was the only factor 
significantly associated with a higher risk of a hemorrhagic complication 
(153).  At a prophylactic dose in the setting of primary prevention of PVT, 
LMWH was proven safe in a recently published prospective study in which 
enoxaparin 4000 UI/day was administered to 34 Child B and C cirrhosis 
patients for 12 months.  No hemorrhagic events were reported, and 
suspension of therapy was necessary in only one patient because of 
thrombocytopenia (164).  
 
In contrast, Garcia Fuster and collaborators reported  bleeding 
complications in 85% of patients (35% of them requiring transfusions) in a 
series of 17 cirrhosis patients treated  with vitamin K antagonists for DVT  
(60). Moreover, an early cohort study evaluating 29,000 INR 
measurements during a period of 6 months, demonstrated that underlying 
liver disease or alcohol abuse were independently correlated with risk of 
excessive anticoagulation (INR≥6) (165). Landefeld and collaborators 
retrospectively evaluated predictors of major bleeding in hospitalized 
patients receiving initial long term warfarin therapy. Among 411 patients 
evaluated for different risk factors, bleeding episodes significantly 
correlated with the presence of worsening liver function (166). 
 
In the present study, one serious adverse event (a non-fatal cerebral 
haemorrhage) occurred which was possibly related to anticoagulation. 
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Risk factors correlated with the underlying liver disease were absent (PLT 
count was 110 x 109/L while INR and creatinine were within the normal 
range).  
 
Heparin induced thrombocytopenia occurred in three patients, and a 
similar high frequency has been reported with the use of LMWH in 
splanchnic vein thrombosis (167).  LWMH was suspended in all three 
patients: one was switched to warfarin, and two patients did not receive 
any anticoagulation treatment.  In all three patients the thrombosis 
remained stable (there was no thrombus progression and no 
recanalization was observed).   
Attainment and maintenance of portal vein patency did not have an impact 
on transplant-free survival, but this is in part due to the fact that PVT is 
more frequent in patients with more advanced cirrhosis, who have a 
greater probability of being transplanted.  If only the event death as such is 
considered, rethrombosis and thrombus progression entailed a mortality of 
80%, and only one of the five deaths in the present series occurred in a 
patient who had adequately responded to therapy.  However, this study 
was not powered to show survival differences, and prolonged follow-up 
studies are needed to assess survival.  
 
Regarding secondary prophylaxis after achieving recanalization, 12 
patients continued prophylactic anticoagulation, and remained free of 
rethrombosis at 6 months’ follow-up.  In contrast, of four patients who had 
achieved complete recanalization but did not continue anticoagulation 
prophylaxis, two had recurrence of the thrombosis, and in one case this 
led to death.  Anticoagulation prophylaxis was also continued in 6 other 
patients after achievement of partial recanalization, and of the four 
patients evaluated six months later, none had presented thrombus 
recurrence. Of 9 patiens in whom recanalization was not achieved even 
after 12 months of therapy, seven continued anticoagulation prophylaxis, 
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and remain stable after 4, and 7 months of follow-up, respectively.  This is 
in contrast with the two patients in whom recanalization was not achieved 
after 12 months of therapy, and in whom prophylactic anticoagulation was 
not continued; these two patients presented progression of the thrombus 
into splanchnic vasculture and one into the vena cava, and led to death in 
both cases.  
 
Although the recommendation to continue anticoagulation in patients with 
PVT who do not obtain recanalization cannot be made based on current 
evidence, the efficacy of anticoagulation in preventing progression of 
thrombosis to a total splanchnic vein thrombosis should be taken into 
consideration, especially in patients who are potential or future candidates 
for  liver transplantation.  
 
Patients with cirrhosis are prone to develop thrombotic complications 
including PVT and DVT. Despite these complications may warrant 
anticoagulant therapy, current treatment guidelines do not provide specific 
indications for anticoagulation in patients with liver disease and 
thrombosis.   
 
Furthermore, low levels of antithrombin, which is necessary for the action 
of low molecular weight heparin, could theoretically hamper  the 
anticoagulant effect of these drugs(116), and data on their use in patients 
with cirrhosis are still limited. Clinically, however, low molecular weight 
heparin is effective in the treatment of thrombotic complications in these 
patients, notwithstanding low levels of antithrombin and low levels of anti-
Xa activity.  Moreover, in a small in vitro study by Lisman and 
collaborators(117),  it was demonstrated that the anti-Xa assay 
substantially underestimates the LMWH mass present in plasma from 
patients with cirrhosis, and actually a fixed amount of LMWH is as effective 
in cirrhotic plasma as it is in plasma from normal pool plasma. 
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Thrombin generation has been recently used to investigate haemostatic 
balance in patients with liver disease and can be useful to evaluate the 
efficacy of LWMH in this setting of patients.  
 
The present study represents an evaluation of the in vitro effect of LMWH 
on thrombin generation in cirrhotic patients, in controls and in a group of 
AT-deficient patients.      
 
Child Pugh C patients demonstrated the greatest response to LMWH, as 
compared to controls.  On the contrary, patients with heterozygous AT 
deficiency showed an in vitro resistance to the effect of LMWH, despite 
similar plasma levels of AT as compared to Child Pugh C cirrhotics. This 
increased effect of LWMH was also evident when a therapeutic dose of 
LMWH was used (0.7 U anti-Xa/mL), which completely inhibited thrombin 
generation in approximately about one-third of cirrhotic patients and 
resulted in a thrombin generation similar to controls in the remaining 
cirrhotic samples.  
 
When the experiments were repeated in samples with the addition of TM 
in order to unveil  the acquired protein C deficiency in patients with 
cirrhosis, the response to the addition of LMWH did not change. Moreover, 
the proportion of plasma samples from patients with more advanced 
cirrhosis (Child C) whose  thrombin generation was completely abated 
after the addition of  LMWH at 0.7 IU/ml was not different between 
samples with and without TM. This confirms the notion that, in cirrhotic 
patients, the  newly rebalanced hemostatic equilibrium due to the 
concomitant decrease in pro-coagulant and anticoagulant factors can be 
easily perturbed.  
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Contrary to what is expected, in cirrhotics the effect of LWMH inversely 
correlated with AT levels. Thus, the  lower the level of AT, the higher the 
anticoagulant response to LWHM. This may be due to the concomitant 
reduction of all procoagulant factors, in particular of factor Xa which is the 
target of LMWH inhibition. On the contrary, subjects with inherited AT 
deficiency had normal plasma levels of all procoagulant factors. As a 
consequence, the reduced effect of LMWH caused by low AT levels, was 
not counterbalanced by the reduction of other procoagulant factors and 
possibly results in the in vitro LMWH resistance. 
 
In agreement with Bechman et al, the present study shows that plasma 
from patients with chronic liver disease present with lower anti-Xa activity 
when a similar dose of LMWH is added, as compared to control plasma. 
However, we also found that in the presence of a lower anti-Xa activity, 
plasma from patients with end stage liver disease exhibited a more 
pronounced response to anticoagulation as compared to control plasma. 
Therefore,  patients in Child Pugh C class, despite very low plasma anti-
Xa activity, demonstrated the highest anticoagulation effect, as opposed to 
what can be seen in patients with isolated AT defect.  
 
This apparently conflicting data can be explained by considering the 
characteristic of the method used to measure anti-Xa activity in the plasma 
sample.  
 
As the test is performed by adding fixed amounts (in excess) of FXa to the 
sample, the result of the reaction depends only on LMWH-AT complex 
generation and concentration.  Adding a fixed amount of LMWH in all 
samples, the differences in the levels of anti-Xa activity depend merely on 
AT plasma levels. Patients with AT deficiency showed similar anti-Xa 
levels to those of Child A cirrhotic patients, and not significantly different 
from that of controls;  this could be due to the difference in the levels of 
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coagulation factors in plasma samples. Theoretically, the test mechanism 
implies  saturation of Xa, and holds true for  plasma of patients with 
normal AT level.   The test’s results could be influenced by decreased 
levels of endogenous FXa, as well as by the  reduced levels of  other 
coagulation factors. 
 
Therefore, anti-Xa determination does not seem to be a suitable test for 
monitoring anticoagulation in cirrhotic patients, since low anti-Xa levels are 
not indicative of a reduction in response to LMWH. On the contrary, the 
present findings show that thrombin generation assay can be useful in the 
evaluation of anticoagulant effect of heparin in cirrhotic patients with 
impaired clotting system. 
 
However, these findings need to be further confirmed in vivo. As the 
matter of fact, an additional influence on pharmacokynetics  and 
distribution of LWMH in cirrhotic patients with ascites may derive from 
altered water content and body mass index, thus leading to unpredictable 
LWMH concentrations. 
 
It is also important to consider that different LWMHs might not have the 
same effect in patients with cirrhosis, due to the different ratio of inhibition 
of factor Xa and thrombin. This ratio can vary from 2.2 to 4.1 among 
commercially available LWMH. For example, enoxaparin, which is 
characterized by an anti- Xa/anti- factor IIa ratio of 3.8, might exert an 
different effect than dalteparin, which has a ratio of 2.7.  
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Aside from the reduction of flow characteristic of portal hypertension and 
cirrhosis, there seems to be an apparent imbalance between pro- and anti-
coagulant factors that could, together with other local factors, contribute to 
the development of PVT.  
The structure of the endothelial lining of the portal vein in cirrhosis patients 
seems to be conserved, and its aspect regarding the endothelial marker 
FVIII is similar to that of other venous territories, exemplified by the vena 
cava, as well as to that of portal vein and vena cava endothelial lining of 
non-cirrhotic subjects. That is, the endothelium of the portal vein in 
cirrhosis patients seems to be characterized by a normal representation of 
FVIII, which is one of the most important drivers of TF-independent 
coagulation.  
On the contrary, the anticoagulation mechanism mediated by TM seems to 
be underrepresented in the portal vein endothelium of cirrhotic patients 
when compared to that of non-cirrhotic subjects. This imbalance, together 
with the mechanical alterations of portal vein flow, may be responsible  for 
the elevated incidence of PVT in cirrhosis patients. Further studies are 
needed regarding other protective mechanisms such as 
glycosaminoglycans and endothelial Protein C receptor. 
 
When PVT develops in cirrhosis patients, anticoagulant therapy with 
LMWH is effective in 65.2% of cases, with achievement of complete portal 
vein patency in 52.2% of patients.  Furthermore, recanalization is achieved 
during the first 6 months of anticoagulation therapy in most patients, but as 
recanalization is reached in yet another, albeit small group of patients who 
continue anticoagulant therapy beyond 6 months, it is worthwhile to 
continue anticoagulation for 12 months.  
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In particular, the hemostatic systemic status does not seem to have an 
impact on the response to anticoagulant therapy, but rather, the interval 
between PVT onset and start of anticoagulation therapy. The continuation 
of anticoagulation at a prophylactic dose for 6 months after recanalization 
seems to be effective in preventing recurrence of PVT after suspension of 
anticoagulation at a therapeutic dose.  
 
Cirrhosis patients therefore demonstrate an adequate clinical response to 
anticoagulant therapy, notwithstanding their low antithrombin levels, 
actually showing a greater susceptibility to increasing concentrations of 
LMWH in advanced cirrhosis, apparent from sharply abated thrombin 
generation curves and decreasing endogenous thrombin potential.  
 
Henceforth, patients with cirrhosis may have an enhanced anticoagulant 
response to LWMH, which increases with the severity of liver disease. 
Anti-X activity is not a good marker of response to LWMH in patients with 
liver disease and should not be used in clinical practice to monitor the 
anticoagulant effect.  
 
Finally, dose adjustment of LWMHs might be  warranted according to the 
Child Pugh class in order to avoid excessive anticoagulation  and possible 
bleeding complications. Clinical studies on the in vivo effect of LMWH in 
cirrhotic patients with thrombosis are needed to further validate this 
hypothesis.   
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